{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:48:02Z","timestamp":1792799282094,"version":"4.5.0"},"reference-count":502,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>PTH-related disorders have a major impact on bone metabolism and skeletal properties because of the pivotal role of PTH in calcium and phosphate homeostasis and bone remodeling. Hyperparathyroidism is characterized by continuous exposure to excessive endogenous PTH, causing increased bone turnover in favor of bone resorption. Depending on the background of PTH overproduction, hyperparathyroidism is divided into primary, secondary, and tertiary hyperparathyroidism. The clinical presentation varies from deterioration of bone microarchitecture and decreased bone mineral density to profound bone involvement, such as osteitis fibrosa cystica and fragility fractures. Although successful parathyroidectomy represents the definitive treatment and may promote regression of most of the skeletal defects, the medical approach of calcimimetics and antiresorptive agents is a promising alternative in cases where parathyroidectomy is not feasible or unsuccessful. Hypoparathyroidism is the pathophysiological counterpart of hyperparathyroidism and also leads to disorders of bone metabolism and structure. Chronic PTH deprivation is associated with low bone remodeling and increased bone mineral density. The defective microarchitecture might affect bone strength and raise the risk for adverse skeletal events. Recombinant human PTH acts as a replacement therapy and is safe and efficient in restoring calcium\/phosphate homeostasis and bone turnover. However, it is approved only for refractory cases, as conventional management with calcium and active vitamin D remains the first-line treatment. This article reviews the skeletal involvement in the most frequent parathyroid disorders, hyperparathyroidism and hypoparathyroidism, and rare familial disorders of PTH metabolism, as assessed by clinical, laboratory, and imaging parameters, and the effect of the available treatment strategies.<\/jats:p>","DOI":"10.1210\/endrev\/bnaf010","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T04:54:39Z","timestamp":1743656079000},"page":"576-620","source":"Crossref","is-referenced-by-count":29,"title":["Bone in Parathyroid Diseases Revisited: Evidence From Epidemiological, Surgical and New Drug Outcomes"],"prefix":"10.1210","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9803-7789","authenticated-orcid":false,"given":"Afroditi","family":"Roumpou","sequence":"first","affiliation":[{"name":"Endocrine and Bone Metabolic Disorders Unit, Second Propaedeutic Department of Internal Medicine, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens , Athens 12462 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[{"name":"Unit of Metabolic Bone and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico , Rome 00128 ,","place":["Italy"]},{"name":"Unit of Endocrinology and Diabetes, Campus Bio-Medico University of Rome , Rome 00128 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8301-324X","authenticated-orcid":false,"given":"Symeon","family":"Tournis","sequence":"additional","affiliation":[{"name":"Laboratory for Research of the Musculoskeletal System \u201cTh. Garofalidis\u201d, Medical School, National and Kapodistrian University of Athens, KAT General Hospital , Kifissia 14561, Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-6662","authenticated-orcid":false,"given":"Valeria","family":"Hasenmajer","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine Sapienza, Endocrine and Andrological Regional, University of Rome , Rome 00185 ,","place":["Italy"]},{"name":"Rare Disease Center (Endo-ERN accredited), Policlinico Umberto I , Rome 00161, Italy, European Reference Network on Rare Endocrine Conditions (ENDO-ERN)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2753-4988","authenticated-orcid":false,"given":"Janice L","family":"Pasieka","sequence":"additional","affiliation":[{"name":"Departments of Surgery and Oncology, University of Calgary , Calgary, Canada AB T2N 2T9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-7883","authenticated-orcid":false,"given":"Gregory","family":"Kaltsas","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolic Diseases, First Department of Propaedeutic and Internal Medicine, General Hospital of Athens LAIKO, School of Medicine, National and Kapodistrian University of Athens , Athens 11527 ,","place":["Greece"]},{"name":"Center of Expertise for Rare Endocrine Diseases (ENDO-ERN accredited), General Hospital of Athens LAIKO, National and Kapodistrian University of Athens , Athens 11527, Greece, European Reference Network on Rare Endocrine Conditions (ENDO-ERN)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9037-5417","authenticated-orcid":false,"given":"Andrea","family":"Isidori","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine Sapienza, Endocrine and Andrological Regional, University of Rome , Rome 00185 ,","place":["Italy"]},{"name":"Rare Disease Center (Endo-ERN accredited), Policlinico Umberto I , Rome 00161 , ,","place":["Italy"]},{"name":"European Reference Network on Rare Endocrine Conditions (ENDO-ERN) , Rome 00161 , ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7491-2297","authenticated-orcid":false,"given":"Eva","family":"Kassi","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolic Diseases, First Department of Propaedeutic and Internal Medicine, General Hospital of Athens LAIKO, School of Medicine, National and Kapodistrian University of Athens , Athens 11527 ,","place":["Greece"]},{"name":"Center of Expertise for Rare Endocrine Diseases (ENDO-ERN accredited), General Hospital of Athens LAIKO, National and Kapodistrian University of Athens , ,","place":["Athens 11527, Greece"]},{"name":"European Reference Network on Rare Endocrine Conditions (ENDO-ERN) , ,","place":["Athens 11527, Greece"]},{"name":"Department of Biogolical Chemistry, School of Medicine, National and Kapodistrian University of Athens, Athens 11527 ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"22","key":"2025071419564133200_bnaf010-B1","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1177\/15353702211010415","article-title":"The role of calcium-sensing receptor signaling in regulating transepithelial calcium transport","volume":"246","author":"Tan","year":"2021","journal-title":"Exp Biol Med"},{"issue":"4","key":"2025071419564133200_bnaf010-B2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ecl.2018.07.003","article-title":"Physiology of parathyroid hormone","volume":"47","author":"Goltzman","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"2025071419564133200_bnaf010-B3","first-page":"249","article-title":"Parathyroid disorders","volume":"88","author":"Michels","year":"2013","journal-title":"Am Fam Physician"},{"issue":"9684","key":"2025071419564133200_bnaf010-B4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","article-title":"Hyperparathyroidism","volume":"374","author":"Fraser","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"2025071419564133200_bnaf010-B5","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1210\/endo-93-6-1349","article-title":"Bovine parathyroid hormone: minimum chain length of synthetic peptide required for biological activity","volume":"93","author":"Tregear","year":"1973","journal-title":"Endocrinology"},{"issue":"5034","key":"2025071419564133200_bnaf010-B6","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.1658941","article-title":"A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide","volume":"254","author":"J\u00fcppner","year":"1991","journal-title":"Science"},{"issue":"4","key":"2025071419564133200_bnaf010-B7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1210\/endrev\/bnab005","article-title":"Physiological and pharmacological roles of PTH and PTHrP in bone using their shared receptor, PTH1R","volume":"42","author":"Martin","year":"2021","journal-title":"Endocr Rev"},{"issue":"10","key":"2025071419564133200_bnaf010-B8","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nchembio.206","article-title":"Sustained cyclic AMP production by parathyroid hormone receptor endocytosis","volume":"5","author":"Ferrandon","year":"2009","journal-title":"Nat Chem Biol"},{"issue":"2","key":"2025071419564133200_bnaf010-B9","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1210\/endo-101-2-555","article-title":"Rat osteogenic sarcoma cells: isolation and effects of hormones on the production of cyclic AMP and cyclic GMP","volume":"101","author":"Atkins","year":"1977","journal-title":"Endocrinology"},{"issue":"10","key":"2025071419564133200_bnaf010-B10","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1016\/S0021-9258(18)50657-8","article-title":"Characterization and comparison of membrane-associated and cytosolic cAMP-dependent protein kinases. Physicochemical and immunological studies on bovine cerebral cortex protein kinases","volume":"254","author":"Rubin","year":"1979","journal-title":"J Biol Chem"},{"issue":"4","key":"2025071419564133200_bnaf010-B11","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1074\/jbc.M412558200","article-title":"Endogenous protein kinase inhibitor \u03b3 terminates immediate-early gene expression induced by cAMP-dependent protein kinase (PKA) signaling","volume":"280","author":"Chen","year":"2005","journal-title":"J Biol Chem"},{"issue":"4","key":"2025071419564133200_bnaf010-B12","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00223-019-00517-0","article-title":"Effect of endogenous parathyroid hormone on bone geometry and skeletal microarchitecture","volume":"104","author":"Hong","year":"2019","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2025071419564133200_bnaf010-B13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor \u03baB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"issue":"2","key":"2025071419564133200_bnaf010-B14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1210\/endo-118-2-824","article-title":"Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone","volume":"118","author":"Mcsheehy","year":"1986","journal-title":"Endocrinology"},{"issue":"3","key":"2025071419564133200_bnaf010-B15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jbmr.1547","article-title":"Osteocyte RANKL: new insights into the control of bone remodeling","volume":"27","author":"Xiong","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2025071419564133200_bnaf010-B16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bone.2012.08.121","article-title":"Osteocyte control of osteoclastogenesis","volume":"54","author":"O\u2019Brien","year":"2013","journal-title":"Bone"},{"issue":"12","key":"2025071419564133200_bnaf010-B17","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","article-title":"Minireview: the OPG\/RANKL\/RANK system","volume":"142","author":"Khosla","year":"2001","journal-title":"Endocrinology"},{"key":"2025071419564133200_bnaf010-B18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bone.2014.06.006","article-title":"Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency","volume":"66","author":"Xiong","year":"2014","journal-title":"Bone"},{"issue":"10","key":"2025071419564133200_bnaf010-B19","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/nm.2448","article-title":"Matrix-embedded cells control osteoclast formation","volume":"17","author":"Xiong","year":"2011","journal-title":"Nat Med"},{"issue":"10","key":"2025071419564133200_bnaf010-B20","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/nm.2452","article-title":"Evidence for osteocyte regulation of bone homeostasis through RANKL expression","volume":"17","author":"Nakashima","year":"2011","journal-title":"Nat Med"},{"issue":"2","key":"2025071419564133200_bnaf010-B21","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1359\/JBMR.0301226","article-title":"PTH differentially regulates expression of RANKL and OPG","volume":"19","author":"Huang","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2025071419564133200_bnaf010-B22","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1210\/endo.142.9.8356","article-title":"Catabolic effects of continuous human PTH (1\u201338) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation","volume":"142","author":"Ma","year":"2001","journal-title":"Endocrinology"},{"issue":"8","key":"2025071419564133200_bnaf010-B23","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1210\/endo.140.8.6887","article-title":"Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation","volume":"140","author":"Lee","year":"1999","journal-title":"Endocrinology"},{"issue":"10","key":"2025071419564133200_bnaf010-B24","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1055\/s-0033-1349842","article-title":"Osteoprotegerin, RANKL, and bone turnover in primary hyperparathyroidism: the effect of parathyroidectomy and treatment with alendronate","volume":"45","author":"Szymczak","year":"2013","journal-title":"Horm Metab Res"},{"issue":"3","key":"2025071419564133200_bnaf010-B25","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1210\/jc.2007-1645","article-title":"The role of the receptor activator of nuclear factor-kappaB ligand\/osteoprotegerin cytokine system in primary hyperparathyroidism","volume":"93","author":"Nakchbandi","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025071419564133200_bnaf010-B26","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bone.2004.03.012","article-title":"Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-\u03bab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism","volume":"35","author":"Stilgren","year":"2004","journal-title":"Bone"},{"issue":"45","key":"2025071419564133200_bnaf010-B27","doi-asserted-by":"crossref","first-page":"33098","DOI":"10.1074\/jbc.M611781200","article-title":"Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of Pre\/osteoclasts","volume":"282","author":"Li","year":"2007","journal-title":"J Biol Chem"},{"issue":"11","key":"2025071419564133200_bnaf010-B28","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.4158\/EP14104.OR","article-title":"Serum monocyte chemokine protein-1 levels before and after parathyroidectomy in patients with primary hyperparathyroidism","volume":"20","author":"Patel","year":"2014","journal-title":"Endocr Pract"},{"issue":"5","key":"2025071419564133200_bnaf010-B29","first-page":"1562","article-title":"On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism 1","volume":"84","author":"Dempster","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025071419564133200_bnaf010-B30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s11154-020-09614-0","article-title":"Skeletal abnormalities in hypoparathyroidism and in primary hyperparathyroidism","volume":"22","author":"Silva","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"issue":"9","key":"2025071419564133200_bnaf010-B31","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1172\/JCI0214817","article-title":"Parathyroid hormone is essential for normal fetal bone formation","volume":"109","author":"Miao","year":"2002","journal-title":"J Clin Invest"},{"issue":"7","key":"2025071419564133200_bnaf010-B32","doi-asserted-by":"crossref","first-page":"e23060","DOI":"10.1371\/journal.pone.0023060","article-title":"Endogenous PTH deficiency impairs fracture healing and impedes the fracture-healing efficacy of exogenous PTH(1\u201334)","volume":"6","author":"Ren","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"2025071419564133200_bnaf010-B33","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1210\/endo.132.2.8425497","article-title":"Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats","volume":"132","author":"Wronski","year":"1993","journal-title":"Endocrinology"},{"issue":"6","key":"2025071419564133200_bnaf010-B34","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1172\/JCI116483","article-title":"Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol","volume":"91","author":"Shen","year":"1993","journal-title":"J Clin Invest"},{"issue":"2","key":"2025071419564133200_bnaf010-B35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1590\/S0004-27302010000200018","article-title":"The use of PTH in the treatment of osteoporosis","volume":"54","author":"Borba","year":"2010","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"6","key":"2025071419564133200_bnaf010-B36","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bone.2007.03.017","article-title":"Molecular and cellular mechanisms of the anabolic effect of intermittent PTH","volume":"40","author":"Jilka","year":"2007","journal-title":"Bone"},{"issue":"6","key":"2025071419564133200_bnaf010-B37","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.bone.2006.09.008","article-title":"Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure","volume":"40","author":"Compston","year":"2007","journal-title":"Bone"},{"issue":"17","key":"2025071419564133200_bnaf010-B38","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2165\/00003495-200565170-00005","article-title":"Parathyroid hormone as an anabolic skeletal therapy","volume":"65","author":"Rubin","year":"2005","journal-title":"Drugs"},{"issue":"2","key":"2025071419564133200_bnaf010-B39","doi-asserted-by":"crossref","first-page":"E594","DOI":"10.1152\/ajpendo.00216.2006","article-title":"Effects of transient PTH on early proliferation, apoptosis, and subsequent differentiation of osteoblast in primary osteoblast cultures","volume":"292","author":"Wang","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"50","key":"2025071419564133200_bnaf010-B40","doi-asserted-by":"crossref","first-page":"50259","DOI":"10.1074\/jbc.M307444200","article-title":"Proteasomal degradation of runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts","volume":"278","author":"Bellido","year":"2003","journal-title":"J Biol Chem"},{"issue":"4","key":"2025071419564133200_bnaf010-B41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1172\/JCI6610","article-title":"Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone","volume":"104","author":"Jilka","year":"1999","journal-title":"J Clin Invest"},{"issue":"11","key":"2025071419564133200_bnaf010-B42","doi-asserted-by":"crossref","first-page":"9787","DOI":"10.1074\/jbc.M110.179127","article-title":"Parathyroid hormone-responsive Smad3-related factor, Tmem119, promotes osteoblast differentiation and interacts with the bone morphogenetic protein-Runx2 pathway","volume":"286","author":"Hisa","year":"2011","journal-title":"J Biol Chem"},{"issue":"3","key":"2025071419564133200_bnaf010-B43","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/me.2002-0225","article-title":"Parathyroid hormone bone anabolic action requires Cbfa1\/Runx2-dependent signaling","volume":"17","author":"Krishnan","year":"2003","journal-title":"Mol Endocrinol"},{"issue":"13","key":"2025071419564133200_bnaf010-B44","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J"},{"issue":"11","key":"2025071419564133200_bnaf010-B45","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1210\/en.2005-0239","article-title":"Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis","volume":"146","author":"Bellido","year":"2005","journal-title":"Endocrinology"},{"issue":"4","key":"2025071419564133200_bnaf010-B46","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/jc.2009-2283","article-title":"Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen Index in postmenopausal women","volume":"95","author":"Mirza","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025071419564133200_bnaf010-B47","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1530\/EJE-10-0699","article-title":"Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls","volume":"163","author":"van Lierop","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2025071419564133200_bnaf010-B48","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00198-011-1806-8","article-title":"Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study","volume":"23","author":"Ardawi","year":"2012","journal-title":"Osteoporos Int"},{"issue":"6","key":"2025071419564133200_bnaf010-B49","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2265.2009.03728.x","article-title":"The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis","volume":"72","author":"Anastasilakis","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025071419564133200_bnaf010-B50","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00774-010-0202-3","article-title":"Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice","volume":"29","author":"Yao","year":"2011","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"2025071419564133200_bnaf010-B51","doi-asserted-by":"crossref","first-page":"030006052096648","DOI":"10.1177\/0300060520966484","article-title":"Severe bone disease caused by primary hyperparathyroidism: a case report and review of the literature","volume":"48","author":"Wang","year":"2020","journal-title":"J Int Med Res"},{"issue":"8","key":"2025071419564133200_bnaf010-B52","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00268-002-6621-0","article-title":"Primary hyperparathyroidism revisited in menopausal women with Serum calcium in the upper normal range at population-based screening 8 years ago","volume":"26","author":"Lundgren","year":"2002","journal-title":"World J Surg"},{"issue":"9","key":"2025071419564133200_bnaf010-B53","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1245\/s10434-012-2378-3","article-title":"The role of gender in primary hyperparathyroidism: same disease, different presentation","volume":"19","author":"Mazeh","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2025071419564133200_bnaf010-B54","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-118-5-199303010-00003","article-title":"Estrogen protection against bone resorbing effects of parathyroid hormone infusion: assessment by use of biochemical markers","volume":"118","author":"Cosman","year":"1993","journal-title":"Ann Intern Med"},{"issue":"3","key":"2025071419564133200_bnaf010-B55","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","article-title":"Raloxifene lowers Serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Rubin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"2025071419564133200_bnaf010-B56","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM198606053142304","article-title":"Ethinyl estradiol and norethindrone in the treatment of primary hyperparathyroidism in postmenopausal women","volume":"314","author":"Selby","year":"1986","journal-title":"N Engl J Med"},{"issue":"12","key":"2025071419564133200_bnaf010-B57","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1001\/jama.2020.0538","article-title":"Diagnosis and management of primary hyperparathyroidism","volume":"323","author":"Zhu","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"2025071419564133200_bnaf010-B58","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/joim.12523","article-title":"Genetics of parathyroid tumours","volume":"280","author":"Thakker","year":"2016","journal-title":"J Intern Med"},{"issue":"8","key":"2025071419564133200_bnaf010-B59","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.3390\/cells10081895","article-title":"Bone and mineral metabolism phenotypes in MEN1-related and sporadic primary hyperparathyroidism, before and after parathyroidectomy","volume":"10","author":"Marini","year":"2021","journal-title":"Cells"},{"issue":"1151","key":"2025071419564133200_bnaf010-B60","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/postgradmedj-2020-137718","article-title":"Urinary calcium indices in primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcaemia (FHH): which test performs best?","volume":"97","author":"Arshad","year":"2021","journal-title":"Postgrad Med J"},{"issue":"11","key":"2025071419564133200_bnaf010-B61","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025071419564133200_bnaf010-B62","doi-asserted-by":"crossref","first-page":"105129","DOI":"10.1016\/j.jbspin.2021.105129","article-title":"Bone and primary hyperparathyroidism","volume":"89","author":"Cormier","year":"2022","journal-title":"Joint Bone Spine"},{"issue":"17-18","key":"2025071419564133200_bnaf010-B63","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10354-013-0235-z","article-title":"Clinical aspects of primary hyperparathyroidism: clinical manifestations, diagnosis, and therapy","volume":"163","author":"Gasser","year":"2013","journal-title":"Wien Med Wochenschr"},{"issue":"10","key":"2025071419564133200_bnaf010-B64","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","article-title":"The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism","volume":"151","author":"Wilhelm","year":"2016","journal-title":"JAMA Surg"},{"issue":"1","key":"2025071419564133200_bnaf010-B65","doi-asserted-by":"crossref","first-page":"7568","DOI":"10.1038\/s41598-023-32707-0","article-title":"Preoperative imaging for hyperparathyroidism often takes upper parathyroid adenomas for lower adenomas","volume":"13","author":"Van den Bruel","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"2025071419564133200_bnaf010-B66","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S8756-3282(97)00078-1","article-title":"Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in danish patients","volume":"21","author":"Christiansen","year":"1997","journal-title":"Bone"},{"issue":"5","key":"2025071419564133200_bnaf010-B67","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S8756-3282(00)00260-X","article-title":"Primary hyperparathyroidism: bone structure, balance, and remodeling before and 3 years after surgical treatment","volume":"26","author":"Steiniche","year":"2000","journal-title":"Bone"},{"issue":"2","key":"2025071419564133200_bnaf010-B68","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1046\/j.1365-2796.1998.00241.x","article-title":"Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease","volume":"243","author":"Valdemarsson","year":"1998","journal-title":"J Intern Med"},{"issue":"1","key":"2025071419564133200_bnaf010-B69","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bone.2013.03.009","article-title":"New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone","volume":"55","author":"Vu","year":"2013","journal-title":"Bone"},{"issue":"5","key":"2025071419564133200_bnaf010-B70","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1210\/jc.2005-2102","article-title":"Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women","volume":"91","author":"Charopoulos","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025071419564133200_bnaf010-B71","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jbmr.5650040302","article-title":"Skeletal disease in primary hyperparathyroidism","volume":"4","author":"Silverberg","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025071419564133200_bnaf010-B72","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bone.2012.11.041","article-title":"\u201cTrabecular bone score\u201d (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism","volume":"53","author":"Romagnoli","year":"2013","journal-title":"Bone"},{"issue":"17","key":"2025071419564133200_bnaf010-B73","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJM199910213411701","article-title":"A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery","volume":"341","author":"Silverberg","year":"1999","journal-title":"N Engl J Med"},{"issue":"8","key":"2025071419564133200_bnaf010-B74","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jbmr.5650070808","article-title":"Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis","volume":"7","author":"Parisien","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2025071419564133200_bnaf010-B75","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/jbmr.1841","article-title":"Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women","volume":"28","author":"Stein","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025071419564133200_bnaf010-B76","doi-asserted-by":"crossref","first-page":"e2527","DOI":"10.1210\/clinem\/dgab207","article-title":"Bone material strength Index as measured by impact microindentation is low in patients with primary hyperparathyroidism","volume":"106","author":"Schoeb","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025071419564133200_bnaf010-B77","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ecl.2016.09.012","article-title":"Primary hyperparathyroidism","volume":"46","author":"Zanocco","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"10","key":"2025071419564133200_bnaf010-B78","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2014-1413","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop","volume":"99","author":"Bilezikian","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025071419564133200_bnaf010-B79","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/jbmr.98","article-title":"Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: a case-control study using HR-pQCT","volume":"25","author":"Hansen","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2025071419564133200_bnaf010-B80","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1210\/jc.2012-4255","article-title":"Trabecular bone score (TBS)\u2014a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism","volume":"98","author":"Silva","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025071419564133200_bnaf010-B81","doi-asserted-by":"crossref","first-page":"e10482","DOI":"10.1002\/jbm4.10482","article-title":"The risk of fractures in primary hyperparathyroidism: a meta-analysis","volume":"5","author":"Narayanan","year":"2021","journal-title":"JBMR Plus"},{"issue":"2","key":"2025071419564133200_bnaf010-B82","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/EJE-13-0305","article-title":"Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism","volume":"169","author":"Eller-Vainicher","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2025071419564133200_bnaf010-B83","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1210\/clinem\/dgab317","article-title":"DXA-Based Bone strain Index: a new tool to evaluate bone quality in primary hyperparathyroidism","volume":"106","author":"Tabacco","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025071419564133200_bnaf010-B84","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1210\/jc.2017-01080","article-title":"Sex difference in the clinical presentation of primary hyperparathyroidism: influence of menopausal Status","volume":"102","author":"Castellano","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025071419564133200_bnaf010-B85","first-page":"123","article-title":"Effect of gender and geographic location on the expression of primary hyperparathyroidism","volume":"36","author":"De Lucia","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"10","key":"2025071419564133200_bnaf010-B86","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1999.14.10.1700","article-title":"Primary hyperparathyroidism and the risk of fracture: a population-based study","volume":"14","author":"Khosla","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"7261","key":"2025071419564133200_bnaf010-B87","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/bmj.321.7261.598","article-title":"Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism","volume":"321","author":"Vestergaard","year":"2000","journal-title":"BMJ"},{"issue":"3","key":"2025071419564133200_bnaf010-B88","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00268-002-6589-9","article-title":"Fractures in patients with primary hyperparathyroidism: nationwide follow-up study of 1201 patients","volume":"27","author":"Vestergaard","year":"2003","journal-title":"World J Surg"},{"issue":"Suppl 2","key":"2025071419564133200_bnaf010-B89","first-page":"N103","article-title":"Fracture risk in primary hyperparathyroidism","volume":"17","author":"Khosla","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025071419564133200_bnaf010-B90","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00198-021-05822-9","article-title":"Risk of fractures in primary hyperparathyroidism: a systematic review and meta-analysis","volume":"32","author":"Ejlsmark-Svensson","year":"2021","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025071419564133200_bnaf010-B91","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/s12891-021-04326-1","article-title":"Osteitis Fibrosa cystica and pathological fractures\u2014the classic but neglected skeletal manifestation of primary hyperparathyroidism: a case report","volume":"22","author":"Vanitcharoenkul","year":"2021","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"2025071419564133200_bnaf010-B92","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/MAJ.0000000000000441","article-title":"Skeletal lesions in primary hyperparathyroidism","volume":"349","author":"Yang","year":"2015","journal-title":"Am J Med Sci"},{"issue":"5","key":"2025071419564133200_bnaf010-B93","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1590\/0004-2730000003381","article-title":"Bone disease in primary hyperparathyroidism","volume":"58","author":"Bandeira","year":"2014","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"2025071419564133200_bnaf010-B94","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.metabol.2017.10.003","article-title":"Bone disease in primary hyperparathyroidism","volume":"80","author":"Makras","year":"2018","journal-title":"Metabolism"},{"issue":"4","key":"2025071419564133200_bnaf010-B95","doi-asserted-by":"crossref","first-page":"e1171","DOI":"10.1210\/clinem\/dgaa084","article-title":"Normocalcemic hyperparathyroidism: study of its prevalence and natural history","volume":"105","author":"Schini","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025071419564133200_bnaf010-B96","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.eprac.2021.04.884","article-title":"Bone quality as measured by trabecular bone score in normocalcemic primary hyperparathyroidism","volume":"27","author":"Naciu","year":"2021","journal-title":"Endocr Pract"},{"issue":"7","key":"2025071419564133200_bnaf010-B97","doi-asserted-by":"crossref","first-page":"dgaa174","DOI":"10.1210\/clinem\/dgaa174","article-title":"Clinical, biochemical, and radiological profile of normocalcemic primary hyperparathyroidism","volume":"105","author":"Palermo","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025071419564133200_bnaf010-B98","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1210\/jc.2006-2802","article-title":"Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype","volume":"92","author":"Lowe","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025071419564133200_bnaf010-B99","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1210\/jc.2003-031014","article-title":"\u201cIncipient\u201d primary hyperparathyroidism: a \u201cforme fruste\u201d of an old disease","volume":"88","author":"Silverberg","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025071419564133200_bnaf010-B100","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1210\/jc.2002-021404","article-title":"Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone","volume":"88","author":"Maruani","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025071419564133200_bnaf010-B101","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00198-023-06669-y","article-title":"DXA-based bone strain index in normocalcemic primary hyperparathyroidism","volume":"34","author":"Tabacco","year":"2023","journal-title":"Osteoporos Int"},{"issue":"2","key":"2025071419564133200_bnaf010-B102","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/cen.12819","article-title":"Normocalcaemic, vitamin D-sufficient hyperparathyroidism\u2014high prevalence and low morbidity in the general population: a long-term follow-up study, the WHO MONICA project, Gothenburg, Sweden","volume":"83","author":"Kontogeorgos","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025071419564133200_bnaf010-B103","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12020-021-02845-4","article-title":"A practical approach to normocalcemic primary hyperparathyroidism","volume":"74","author":"Mu\u00f1oz de Nova","year":"2021","journal-title":"Endocrine"},{"issue":"6","key":"2025071419564133200_bnaf010-B104","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jcem-67-6-1294","article-title":"Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course","volume":"67","author":"Rao","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025071419564133200_bnaf010-B105","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1210\/jc.2006-1836","article-title":"Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial","volume":"92","author":"Bollerslev","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025071419564133200_bnaf010-B106","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1210\/jc.2004-0028","article-title":"Randomized controlled clinical trial of surgery Versus No surgery in patients with mild asymptomatic primary hyperparathyroidism","volume":"89","author":"Rao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025071419564133200_bnaf010-B107","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S8756-3282(98)00042-8","article-title":"Bone measurements in asymptomatic primary hyperparathyroidism","volume":"22","author":"Adami","year":"1998","journal-title":"Bone"},{"issue":"1","key":"2025071419564133200_bnaf010-B108","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12020-023-03491-8","article-title":"Site specific differences in vBMD and geometry in postmenopausal women with primary hyperparathyroidism","volume":"83","author":"Karlafti","year":"2023","journal-title":"Endocrine"},{"issue":"3","key":"2025071419564133200_bnaf010-B109","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s00774-016-0751-1","article-title":"The natural history and hip geometric changes of primary hyperparathyroidism without parathyroid surgery","volume":"35","author":"Jung","year":"2017","journal-title":"J Bone Miner Metab"},{"issue":"9","key":"2025071419564133200_bnaf010-B110","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1210\/jc.2007-1215","article-title":"The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years","volume":"93","author":"Rubin","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025071419564133200_bnaf010-B111","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker R","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025071419564133200_bnaf010-B112","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13023-020-01380-1","article-title":"Bone tissue and mineral metabolism in hereditary endocrine tumors: clinical manifestations and genetic bases","volume":"15","author":"Maraghelli","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2025071419564133200_bnaf010-B113","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1359\/jbmr.090304","article-title":"Sporadic and MEN1-related primary hyperparathyroidism: differences in clinical expression and severity","volume":"24","author":"Eller-Vainicher","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025071419564133200_bnaf010-B114","first-page":"573","article-title":"Peripheral bone mineral density in correlation to disease-related predisposing conditions in patients with multiple endocrine neoplasia type 1","volume":"35","author":"Kann","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"2025071419564133200_bnaf010-B115","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.3390\/jcm11071967","article-title":"Management and long-term follow-up of hyperparathyroidism in multiple endocrine neoplasia type 1: single center experience","volume":"11","author":"Yavropoulou","year":"2022","journal-title":"J Clin Med"},{"issue":"10","key":"2025071419564133200_bnaf010-B116","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/archsurg.134.10.1119","article-title":"Osteoporosis in multiple endocrine neoplasia type 1","volume":"134","author":"Burgess","year":"1999","journal-title":"Archives of Surgery"},{"issue":"1","key":"2025071419564133200_bnaf010-B117","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00198-019-05186-1","article-title":"Impaired geometry, volumetric density, and microstructure of cortical and trabecular bone assessed by HR-pQCT in both sporadic and MEN1-related primary hyperparathyroidism","volume":"31","author":"Wang","year":"2020","journal-title":"Osteoporos Int"},{"issue":"11","key":"2025071419564133200_bnaf010-B118","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1002\/jbmr.125","article-title":"Early-onset, progressive, frequent, extensive, and severe bone mineral and renal complications in multiple endocrine neoplasia type 1-associated primary hyperparathyroidism","volume":"25","author":"Louren\u00e7o","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025071419564133200_bnaf010-B119","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/clinem\/dgad460","article-title":"Trabecular bone score as a more sensitive tool to evaluate bone involvement in MEN1-related primary hyperparathyroidism","volume":"109","author":"Song","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025071419564133200_bnaf010-B120","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1074\/jbc.M114.629899","article-title":"Osteoblast menin regulates bone mass in vivo","volume":"290","author":"Kanazawa","year":"2015","journal-title":"J Biol Chem"},{"issue":"1","key":"2025071419564133200_bnaf010-B121","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ydbio.2009.05.555","article-title":"Menin expression modulates mesenchymal cell commitment to the myogenic and osteogenic lineages","volume":"332","author":"Aziz","year":"2009","journal-title":"Dev Biol"},{"issue":"4","key":"2025071419564133200_bnaf010-B122","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.otc.2004.02.005","article-title":"Hyperparathyroidism and multiple endocrine neoplasia","volume":"37","author":"Malone","year":"2004","journal-title":"Otolaryngol Clin North Am"},{"issue":"12","key":"2025071419564133200_bnaf010-B123","doi-asserted-by":"crossref","first-page":"e4371","DOI":"10.1210\/clinem\/dgac500","article-title":"Fracture risk in pediatric patients with MEN2B","volume":"107","author":"Li","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025071419564133200_bnaf010-B124","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/cen.14644","article-title":"Genetics of monogenic disorders of calcium and bone metabolism","volume":"97","author":"Newey","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2025071419564133200_bnaf010-B125","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s42000-023-00508-9","article-title":"Genetics of hereditary forms of primary hyperparathyroidism","volume":"23","author":"English","year":"2024","journal-title":"Hormones"},{"issue":"3","key":"2025071419564133200_bnaf010-B126","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s12020-021-02620-5","article-title":"Rare diseases caused by abnormal calcium sensing and signalling","volume":"71","author":"T\u0151ke","year":"2021","journal-title":"Endocrine"},{"issue":"6","key":"2025071419564133200_bnaf010-B127","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2265.2009.03557.x","article-title":"Skeletal consequences of familial hypocalciuric hypercalcaemia vs. Primary hyperparathyroidism","volume":"71","author":"Christensen","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025071419564133200_bnaf010-B128","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00223-011-9517-x","article-title":"Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study","volume":"89","author":"Isaksen","year":"2011","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"2025071419564133200_bnaf010-B129","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/cen.14211","article-title":"Clinical characteristics of familial hypocalciuric hypercalcaemia type 1: a multicentre study of 77 adult patients","volume":"93","author":"Mouly","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2025071419564133200_bnaf010-B130","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00223-014-9877-0","article-title":"Increased trabecular volumetric bone mass density in familial hypocalciuric hypercalcemia (FHH) type 1: a cross-sectional study","volume":"95","author":"Jakobsen","year":"2014","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2025071419564133200_bnaf010-B131","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1210\/jc.2015-3442","article-title":"Familial hypocalciuric hypercalcemia types 1 and 3 and primary hyperparathyroidism: similarities and differences","volume":"101","author":"Vargas-Poussou","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"2025071419564133200_bnaf010-B132","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1093\/hmg\/ddv226","article-title":"Adaptor protein-2 sigma subunit mutations causing familial hypocalciuric hypercalcaemia type 3 (FHH3) demonstrate genotype\u2013phenotype correlations, codon bias and dominant-negative effects","volume":"24","author":"Hannan","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"11","key":"2025071419564133200_bnaf010-B133","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/jbmr.4685","article-title":"The efficacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Ye","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025071419564133200_bnaf010-B134","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.surg.2006.06.016","article-title":"Improvement in the health-related quality-of-life symptoms of hyperparathyroidism is durable on long-term follow-up","volume":"140","author":"Edwards","year":"2006","journal-title":"Surgery"},{"issue":"11","key":"2025071419564133200_bnaf010-B135","doi-asserted-by":"crossref","first-page":"715","DOI":"10.7326\/M15-1232","article-title":"The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism","volume":"164","author":"Yeh","year":"2016","journal-title":"Ann Intern Med"},{"issue":"3","key":"2025071419564133200_bnaf010-B136","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12020-020-02401-6","article-title":"Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism","volume":"69","author":"Miyaoka","year":"2020","journal-title":"Endocrine"},{"issue":"2","key":"2025071419564133200_bnaf010-B137","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s12020-016-1101-8","article-title":"Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism","volume":"55","author":"Cipriani","year":"2017","journal-title":"Endocrine"},{"issue":"2","key":"2025071419564133200_bnaf010-B138","doi-asserted-by":"crossref","first-page":"330","DOI":"10.3390\/jcm11020330","article-title":"Bone mineral density compared to trabecular bone score in primary hyperparathyroidism","volume":"11","author":"Jones","year":"2022","journal-title":"J Clin Med"},{"issue":"9","key":"2025071419564133200_bnaf010-B139","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/archsurg.141.9.885","article-title":"The effect of parathyroidectomy on bone fracture risk in patients with primary hyperparathyroidism","volume":"141","author":"VanderWalde","year":"2006","journal-title":"Archives of Surgery"},{"issue":"1","key":"2025071419564133200_bnaf010-B140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1001\/jamainternmed.2021.6437","article-title":"Risk of fracture among older adults with primary hyperparathyroidism receiving parathyroidectomy vs nonoperative management","volume":"182","author":"Seib","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2025071419564133200_bnaf010-B141","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1067\/msy.2002.128484","article-title":"Recovery pattern of patients with osteitis fibrosa cystica in primary hyperparathyroidism after successful parathyroidectomy","volume":"132","author":"Agarwal","year":"2002","journal-title":"Surgery"},{"issue":"5","key":"2025071419564133200_bnaf010-B142","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1590\/2359-3997000000088","article-title":"Regression of orbital brown tumor after surgical removal of parathyroid adenoma","volume":"59","author":"de Oliveira","year":"2015","journal-title":"Arch Endocrinol Metab"},{"key":"2025071419564133200_bnaf010-B143","doi-asserted-by":"crossref","first-page":"11795514231210143","DOI":"10.1177\/11795514231210143","article-title":"Brown tumors of the jaws: a retrospective study","volume":"16","author":"Fedhila","year":"2023","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"8","key":"2025071419564133200_bnaf010-B144","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1210\/jc.2013-1518","article-title":"Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism","volume":"98","author":"Koumakis","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025071419564133200_bnaf010-B145","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1210\/jc.2007-0219","article-title":"Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial","volume":"92","author":"Ambrogini","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025071419564133200_bnaf010-B146","first-page":"CD013035","article-title":"Parathyroidectomy for adults with primary hyperparathyroidism","volume":"3","author":"Pappachan","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2025071419564133200_bnaf010-B147","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1210\/clinem\/dgad718","article-title":"Parathyroidectomy improves bone density in women with primary hyperparathyroidism and preoperative osteopenia","volume":"109","author":"Frey","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025071419564133200_bnaf010-B148","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1002\/jbmr.3177","article-title":"Effect of surgery versus observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH study)","volume":"32","author":"Lundstam","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025071419564133200_bnaf010-B149","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/jbmr.4763","article-title":"Positive effect of parathyroidectomy compared to observation on BMD in a randomized controlled trial of mild primary hyperparathyroidism","volume":"38","author":"Lundstam","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025071419564133200_bnaf010-B150","doi-asserted-by":"crossref","first-page":"812","DOI":"10.7326\/M21-4416","article-title":"Mortality and morbidity in mild primary hyperparathyroidism: results from a 10-year prospective randomized controlled trial of parathyroidectomy versus observation","volume":"175","author":"Pretorius","year":"2022","journal-title":"Ann Intern Med"},{"issue":"10","key":"2025071419564133200_bnaf010-B151","doi-asserted-by":"crossref","first-page":"e1922","DOI":"10.1210\/clinem\/dgae326","article-title":"Skeletal effect of parathyroidectomy on patients with primary hyperparathyroidism: a systematic review and meta-analysis","volume":"109","author":"Kongsaree","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025071419564133200_bnaf010-B152","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.3390\/cancers15123085","article-title":"Comparison of medical management versus parathyroidectomy in patients with mild primary hyperparathyroidism: a meta-analysis","volume":"15","author":"Cironi","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025071419564133200_bnaf010-B153","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.surg.2016.06.065","article-title":"Operative intervention for primary hyperparathyroidism offers greater bone recovery in patients with sporadic disease than in those with multiple endocrine neoplasia type 1\u2013related hyperparathyroidism","volume":"161","author":"Silva","year":"2017","journal-title":"Surgery"},{"issue":"6","key":"2025071419564133200_bnaf010-B154","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.beem.2018.09.010","article-title":"Management of familial hyperparathyroidism syndromes: MEN1, MEN2, MEN4, HPT-jaw tumour, familial isolated hyperparathyroidism, FHH, and neonatal severe hyperparathyroidism","volume":"32","author":"Cristina","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"2025071419564133200_bnaf010-B155","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1530\/EJE-12-0528","article-title":"THERAPY OF ENDOCRINE DISEASE: hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature","volume":"168","author":"Witteveen","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025071419564133200_bnaf010-B156","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1457496920962601","article-title":"Role of vitamin D supplements in prevention of hungry bone syndrome after successful parathyroidectomy for primary hyperparathyroidism: a prospective study","volume":"110","author":"Salman","year":"2021","journal-title":"Scand J Surg"},{"issue":"11","key":"2025071419564133200_bnaf010-B157","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.3390\/diagnostics13111953","article-title":"Forestalling hungry bone syndrome after parathyroidectomy in patients with primary and renal hyperparathyroidism","volume":"13","author":"Carsote","year":"2023","journal-title":"Diagnostics"},{"issue":"1","key":"2025071419564133200_bnaf010-B158","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/2230-8210.196023","article-title":"Preoperative zoledronic acid therapy prevent hungry bone syndrome in patients with primary hyperparathyroidism","volume":"21","author":"Mayilvaganan","year":"2017","journal-title":"Indian J Endocrinol Metab"},{"issue":"2","key":"2025071419564133200_bnaf010-B159","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/a-1325-0351","article-title":"Role of bisphosphonates in the prevention of postoperative hungry bone syndrome in primary hyperparathyroidism: a meta-analysis and need for randomized controlled trials","volume":"71","author":"Pal","year":"2021","journal-title":"Drug Res"},{"key":"2025071419564133200_bnaf010-B160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fendo.2017.00079","article-title":"Contemporary medical management of primary hyperparathyroidism: a systematic review","volume":"8","author":"Leere","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2025071419564133200_bnaf010-B161","doi-asserted-by":"crossref","first-page":"689","DOI":"10.20945\/2359-3997000000558","article-title":"Medical management of primary hyperparathyroidism","volume":"66","author":"Bandeira","year":"2022","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"2025071419564133200_bnaf010-B162","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jgs.15250","article-title":"Protective effect of denosumab on bone in older women with primary hyperparathyroidism","volume":"66","author":"Eller-Vainicher","year":"2018","journal-title":"J Am Geriatr Soc"},{"issue":"12","key":"2025071419564133200_bnaf010-B163","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study","volume":"94","author":"Peacock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025071419564133200_bnaf010-B164","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","article-title":"The calcimimetic cinacalcet normalizes Serum calcium in subjects with primary hyperparathyroidism","volume":"88","author":"Shoback","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025071419564133200_bnaf010-B165","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1210\/jc.2010-1221","article-title":"Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide Spectrum of disease severity","volume":"96","author":"Peacock","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"7749","key":"2025071419564133200_bnaf010-B166","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0140-6736(72)90173-0","article-title":"TREATMENT WITH \u0152STROGENS OF PRIMARY HYPERPARATHYROIDISM IN POST-MENOPAUSAL WOMEN","volume":"299","author":"Gallagher","year":"1972","journal-title":"The Lancet"},{"issue":"5","key":"2025071419564133200_bnaf010-B167","doi-asserted-by":"crossref","first-page":"360","DOI":"10.7326\/0003-4819-125-5-199609010-00002","article-title":"Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism","volume":"125","author":"Grey","year":"1996","journal-title":"Ann Intern Med"},{"issue":"14","key":"2025071419564133200_bnaf010-B168","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1001\/archinte.160.14.2161","article-title":"Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism","volume":"160","author":"Orr-Walker","year":"2000","journal-title":"Arch Intern Med"},{"issue":"1","key":"2025071419564133200_bnaf010-B169","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1359\/jbmr.2001.16.1.189","article-title":"Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism","volume":"16","author":"Zanchetta","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2025071419564133200_bnaf010-B170","first-page":"1076","article-title":"Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism","volume":"36","author":"Akbaba","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2025071419564133200_bnaf010-B171","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","journal-title":"Endocrine"},{"issue":"5","key":"2025071419564133200_bnaf010-B172","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2025071419564133200_bnaf010-B173","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00394-002-0383-1","article-title":"The effects of calcium supplementation to patients with primary hyperparathyroidism and a low calcium intake","volume":"41","author":"Jorde","year":"2002","journal-title":"Eur J Nutr"},{"issue":"6","key":"2025071419564133200_bnaf010-B174","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/cen.12398","article-title":"Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature","volume":"80","author":"Shah","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2025071419564133200_bnaf010-B175","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s40618-020-01473-5","article-title":"Safety and efficacy of common vitamin D supplementation in primary hyperparathyroidism and coexistent vitamin D deficiency and insufficiency: a systematic review and meta-analysis","volume":"44","author":"Song","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"2025071419564133200_bnaf010-B176","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3390\/jcm10081604","article-title":"Primary hyperparathyroidism: a narrative review of diagnosis and medical management","volume":"10","author":"Dandurand","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"2025071419564133200_bnaf010-B177","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025071419564133200_bnaf010-B178","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1359\/jbmr.2001.16.1.113","article-title":"Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism","volume":"16","author":"Rossini","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025071419564133200_bnaf010-B179","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11154-021-09694-6","article-title":"The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies","volume":"23","author":"Chandran","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"issue":"Suppl 2","key":"2025071419564133200_bnaf010-B180","first-page":"N150","article-title":"Bisphosphonates and primary hyperparathyroidism","volume":"17","author":"Rodan","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025071419564133200_bnaf010-B181","first-page":"871","article-title":"[Alendronate increases bone mineral density in patients with symptomatic primary hyperparathyroidism]","volume":"56","author":"Misiorowski","year":"2005","journal-title":"Endokrynol Pol"},{"issue":"4","key":"2025071419564133200_bnaf010-B182","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00198-014-3000-2","article-title":"Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism","volume":"26","author":"Cesareo","year":"2015","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025071419564133200_bnaf010-B183","first-page":"1067","article-title":"Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate","volume":"77","author":"Reasner","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025071419564133200_bnaf010-B184","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00774-013-0473-6","article-title":"Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism","volume":"32","author":"Tournis","year":"2014","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"2025071419564133200_bnaf010-B185","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1185\/030079903125003062","article-title":"Is bone mineral density predictive of fracture risk reduction?","volume":"20","author":"Cefalu","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"2025071419564133200_bnaf010-B186","doi-asserted-by":"crossref","first-page":"1098841","DOI":"10.3389\/fendo.2023.1098841","article-title":"Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: a systematic review and meta-analysis","volume":"14","author":"Rajput","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2025071419564133200_bnaf010-B187","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40266-018-0525-7","article-title":"Denosumab: a review in postmenopausal osteoporosis","volume":"35","author":"Deeks","year":"2018","journal-title":"Drugs Aging"},{"issue":"2","key":"2025071419564133200_bnaf010-B188","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12020-023-03381-z","article-title":"Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency","volume":"81","author":"Gronskaya","year":"2023","journal-title":"Endocrine"},{"issue":"8","key":"2025071419564133200_bnaf010-B189","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00198-018-4533-6","article-title":"Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies","volume":"29","author":"Thongprayoon","year":"2018","journal-title":"Osteoporos Int"},{"issue":"6","key":"2025071419564133200_bnaf010-B190","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00223-020-00754-8","article-title":"A simple-to-use score for identifying individuals at high risk of denosumab-associated hypocalcemia in postmenopausal osteoporosis: a real-world cohort study","volume":"107","author":"Kim","year":"2020","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"2025071419564133200_bnaf010-B191","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jama.2023.28239","article-title":"Severe hypocalcemia with denosumab among older female dialysis-dependent patients","volume":"331","author":"Bird","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"2025071419564133200_bnaf010-B192","first-page":"669","article-title":"Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism","volume":"65","author":"Kuchay","year":"2021","journal-title":"Arch Endocrinol Metab"},{"issue":"2","key":"2025071419564133200_bnaf010-B193","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/ijem.IJEM_678_18","article-title":"Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to primary hyperparathyroidism in the setting of renal dysfunction","volume":"23","author":"Rajan","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"issue":"4","key":"2025071419564133200_bnaf010-B194","doi-asserted-by":"crossref","first-page":"e233665","DOI":"10.1136\/bcr-2019-233665","article-title":"Pitfalls of using denosumab preoperatively to treat refractory severe hypercalcaemia","volume":"13","author":"Li","year":"2020","journal-title":"BMJ Case Rep"},{"key":"2025071419564133200_bnaf010-B195","doi-asserted-by":"crossref","first-page":"115048","DOI":"10.1016\/j.bone.2019.115048","article-title":"Off-label uses of denosumab in metabolic bone diseases","volume":"129","author":"Polyzos","year":"2019","journal-title":"Bone"},{"issue":"8","key":"2025071419564133200_bnaf010-B196","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/imj.13508","article-title":"Denosumab-induced hypophosphataemia in a case of normocalcaemic primary hyperparathyroidism","volume":"47","author":"Konrade","year":"2017","journal-title":"Intern Med J"},{"issue":"3","key":"2025071419564133200_bnaf010-B197","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s12020-011-9452-7","article-title":"Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects","volume":"39","author":"Duntas","year":"2011","journal-title":"Endocrine"},{"issue":"4","key":"2025071419564133200_bnaf010-B198","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00774-020-01190-2","article-title":"Reduction in parathyroid adenomas by cinacalcet therapy in patients with primary hyperparathyroidism","volume":"39","author":"Minezaki","year":"2021","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"2025071419564133200_bnaf010-B199","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12020-015-0696-5","article-title":"Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to multiple endocrine neoplasia syndrome type 1 (MEN1)","volume":"52","author":"Giusti","year":"2016","journal-title":"Endocrine"},{"issue":"3","key":"2025071419564133200_bnaf010-B200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.pharmthera.2005.06.019","article-title":"Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism","volume":"109","author":"Nagano","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"4","key":"2025071419564133200_bnaf010-B201","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.metabol.2007.11.014","article-title":"Cinacalcet for the treatment of primary hyperparathyroidism","volume":"57","author":"Sajid-Crockett","year":"2008","journal-title":"Metabolism"},{"issue":"2","key":"2025071419564133200_bnaf010-B202","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/MAJ.0b013e3181379f3e","article-title":"Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy","volume":"335","author":"Iglesias","year":"2008","journal-title":"Am J Med Sci"},{"issue":"11","key":"2025071419564133200_bnaf010-B203","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1530\/EC-21-0258","article-title":"A single-centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism","volume":"10","author":"Bell","year":"2021","journal-title":"Endocr Connect"},{"issue":"5","key":"2025071419564133200_bnaf010-B204","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/EJE-14-0877","article-title":"Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery","volume":"172","author":"Khan","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2025071419564133200_bnaf010-B205","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1530\/EC-20-0221","article-title":"Cinacalcet and primary hyperparathyroidism: systematic review and meta regression","volume":"9","author":"Ng","year":"2020","journal-title":"Endocr Connect"},{"issue":"6","key":"2025071419564133200_bnaf010-B206","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1530\/EJE-14-0355","article-title":"The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice","volume":"171","author":"Schwarz","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025071419564133200_bnaf010-B207","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/2042018813482344","article-title":"Experience with cinacalcet in primary hyperparathyroidism: results after 1 year of treatment","volume":"4","author":"Luque-Fern\u00e1ndez","year":"2013","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"8","key":"2025071419564133200_bnaf010-B208","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1507\/endocrj.EJ19-0034","article-title":"Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience","volume":"66","author":"Manaka","year":"2019","journal-title":"Endocr J"},{"issue":"2","key":"2025071419564133200_bnaf010-B209","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1210\/jc.2008-1762","article-title":"Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop","volume":"94","author":"Khan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025071419564133200_bnaf010-B210","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.2215\/CJN.02110310","article-title":"Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism","volume":"5","author":"Komaba","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2025071419564133200_bnaf010-B211","doi-asserted-by":"crossref","first-page":"c195","DOI":"10.1159\/000313035","article-title":"Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism","volume":"115","author":"Ichii","year":"2010","journal-title":"Nephron Clin Pract"},{"issue":"3","key":"2025071419564133200_bnaf010-B212","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/ndt\/gfn654","article-title":"Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism","volume":"24","author":"Meola","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3-4","key":"2025071419564133200_bnaf010-B213","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000357951","article-title":"Cinacalcet induces apoptosis in parathyroid cells in patients with secondary hyperparathyroidism: histological and cytological analyses","volume":"124","author":"Tatsumi","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"2025071419564133200_bnaf010-B214","doi-asserted-by":"crossref","first-page":"2324709620936836","DOI":"10.1177\/2324709620936836","article-title":"Cinacalcet-associated resolution of primary hyperparathyroidism in a patient with normal kidney function","volume":"8","author":"Nguyen","year":"2020","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"6","key":"2025071419564133200_bnaf010-B215","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/ncpendmet0816","article-title":"A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet","volume":"4","author":"Falchetti","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"2","key":"2025071419564133200_bnaf010-B216","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1530\/EJE-12-0117","article-title":"MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly","volume":"167","author":"Filopanti","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"2025071419564133200_bnaf010-B217","doi-asserted-by":"crossref","first-page":"906163","DOI":"10.1155\/2010\/906163","article-title":"Clinical use of cinacalcet in MEN1 hyperparathyroidism","volume":"2010","author":"Moyes","year":"2010","journal-title":"Int J Endocrinol"},{"key":"2025071419564133200_bnaf010-B218","doi-asserted-by":"crossref","first-page":"e6390","DOI":"10.1136\/bmj.e6390","article-title":"Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study","volume":"345","author":"Paik","year":"2012","journal-title":"BMJ"},{"issue":"6","key":"2025071419564133200_bnaf010-B219","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0002-9343(97)00053-3","article-title":"Optimal dietary calcium intake in primary hyperparathyroidism","volume":"102","author":"Locker","year":"1997","journal-title":"Am J Med"},{"issue":"5","key":"2025071419564133200_bnaf010-B220","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2265.2005.02371.x","article-title":"Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism","volume":"63","author":"Moosgaard","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025071419564133200_bnaf010-B221","doi-asserted-by":"crossref","first-page":"105616","DOI":"10.1016\/j.jsbmb.2020.105616","article-title":"Lower total 25-hydroxyvitamin D but no difference in calculated or measured free 25-hydroxyvitamin D serum levels in patients with primary hyperparathyroidism","volume":"199","author":"Meng","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"2","key":"2025071419564133200_bnaf010-B222","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40618-021-01633-1","article-title":"Total and free vitamin D metabolites in patients with primary hyperparathyroidism","volume":"45","author":"Meng","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2025071419564133200_bnaf010-B223","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1308\/rcsann.2021.0078","article-title":"Vitamin D repletion in primary hyperparathyroid patients undergoing parathyroidectomy leads to reduced symptomatic hypocalcaemia and reduced length of stay: a retrospective cohort study","volume":"104","author":"Acharya","year":"2022","journal-title":"Ann R Coll Surg Engl"},{"issue":"1","key":"2025071419564133200_bnaf010-B224","doi-asserted-by":"crossref","first-page":"9895","DOI":"10.1038\/s41598-020-66889-8","article-title":"Preoperative vitamin D levels as a predictor of transient hypocalcemia and hypoparathyroidism after parathyroidectomy","volume":"10","author":"Unsal","year":"2020","journal-title":"Sci Rep"},{"key":"2025071419564133200_bnaf010-B225","doi-asserted-by":"crossref","first-page":"105695","DOI":"10.1016\/j.jsbmb.2020.105695","article-title":"Effect of vitamin D nutrition on disease indices in patients with primary hyperparathyroidism","volume":"201","author":"Rao","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"10","key":"2025071419564133200_bnaf010-B226","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1210\/jc.2014-1417","article-title":"Medical management of primary hyperparathyroidism: proceedings of the fourth international workshop on the management of asymptomatic primary hyperparathyroidism","volume":"99","author":"Marcocci","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025071419564133200_bnaf010-B227","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1007\/s00198-017-3918-2","article-title":"Skeletal effects of vitamin D deficiency among patients with primary hyperparathyroidism","volume":"28","author":"Lee","year":"2017","journal-title":"Osteoporos Int"},{"issue":"9","key":"2025071419564133200_bnaf010-B228","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1210\/jc.2015-2022","article-title":"Vitamin D in primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation","volume":"100","author":"Walker","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025071419564133200_bnaf010-B229","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1210\/jc.2015-4218","article-title":"Effect of low vitamin D on volumetric bone mineral density, bone microarchitecture, and stiffness in primary hyperparathyroidism","volume":"101","author":"Walker","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025071419564133200_bnaf010-B230","doi-asserted-by":"crossref","first-page":"221","DOI":"10.23736\/S0391-1977.17.02584-6","article-title":"Effect of vitamin D replacement in primary hyperparathyroidism with concurrent vitamin D deficiency: a systematic review and meta-analysis","volume":"44","author":"Loh","year":"2019","journal-title":"Minerva Endocrinol"},{"issue":"4","key":"2025071419564133200_bnaf010-B231","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1530\/EJE-21-0322","article-title":"Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study","volume":"185","author":"Ryh\u00e4nen","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025071419564133200_bnaf010-B232","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.surg.2019.04.059","article-title":"Skeletal effects of combined medical and surgical management of primary hyperparathyroidism","volume":"167","author":"Orr","year":"2020","journal-title":"Surgery"},{"issue":"2","key":"2025071419564133200_bnaf010-B233","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s00774-021-01279-2","article-title":"Skeletal effects of combined bisphosphonates treatment and parathyroidectomy in osteoporotic patients with primary hyperparathyroidism","volume":"40","author":"Choe","year":"2022","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"2025071419564133200_bnaf010-B234","first-page":"131","article-title":"Bisphosphonates can reduce bone hunger after parathyroidectomy in patients with primary hyperparathyroidism and osteitis fibrosa cystica","volume":"51","author":"de Fran\u00e7a","year":"2011","journal-title":"Rev Bras Reumatol"},{"issue":"3","key":"2025071419564133200_bnaf010-B235","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00774-005-0680-x","article-title":"Bisphosphonate pretreatment attenuates hungry bone syndrome postoperatively in subjects with primary hyperparathyroidism","volume":"24","author":"Lee","year":"2006","journal-title":"J Bone Miner Metab"},{"key":"2025071419564133200_bnaf010-B236","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000491039","article-title":"Parathyroid carcinoma","volume":"51","author":"Cetani","year":"2019","journal-title":"Front Horm Res"},{"issue":"1","key":"2025071419564133200_bnaf010-B237","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11864-011-0171-3","article-title":"Parathyroid carcinoma: update and guidelines for management","volume":"13","author":"Wei","year":"2012","journal-title":"Curr Treat Options Oncol"},{"key":"2025071419564133200_bnaf010-B238","first-page":"bcr2013203396","article-title":"Bone resorption in parathyroid carcinoma","volume":"2014","author":"Naderi","year":"2014","journal-title":"Case Rep"},{"issue":"9","key":"2025071419564133200_bnaf010-B239","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/bjs.1800750914","article-title":"Hyperparathyroidism after neck irradiation","volume":"75","author":"Christmas","year":"2005","journal-title":"Br J Surg"},{"issue":"10","key":"2025071419564133200_bnaf010-B240","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1136\/jcp.38.10.1114","article-title":"Parathyroid carcinoma associated with chronic renal failure and previous radiotherapy to the neck","volume":"38","author":"Ireland","year":"1985","journal-title":"J Clin Pathol"},{"issue":"2","key":"2025071419564133200_bnaf010-B241","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jamcollsurg.2004.04.014","article-title":"Parathyroid carcinoma in secondary and tertiary hyperparathyroidism1","volume":"199","author":"Khan","year":"2004","journal-title":"J Am Coll Surg"},{"issue":"7","key":"2025071419564133200_bnaf010-B242","first-page":"349","article-title":"Concurrent primary parathyroid hyperplasia and parathyroid carcinoma","volume":"107","author":"Haghighi","year":"1983","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"2025071419564133200_bnaf010-B243","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4158\/EP09075.CRR","article-title":"Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidism","volume":"15","author":"Goldfarb","year":"2009","journal-title":"Endocr Pract"},{"issue":"3","key":"2025071419564133200_bnaf010-B244","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00774-011-0344-y","article-title":"Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism","volume":"30","author":"Campenn\u00ec","year":"2012","journal-title":"J Bone Miner Metab"},{"issue":"12","key":"2025071419564133200_bnaf010-B245","first-page":"1956","article-title":"Pathological bone fractures in a patient with parathyroid carcinoma\u2014a case report","volume":"67","author":"Shahid","year":"2017","journal-title":"J Pak Med Assoc"},{"issue":"4","key":"2025071419564133200_bnaf010-B246","first-page":"229","article-title":"[Parathyroid carcinoma: diagnosis by a femur fracture]","volume":"32","author":"Dom\u00ednguez-Gasca","year":"2018","journal-title":"Acta Ortop Mex"},{"issue":"1","key":"2025071419564133200_bnaf010-B247","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1186\/s13104-018-3711-0","article-title":"Case report: lady with bone pains for 5 years\u2014parathyroid carcinoma","volume":"11","author":"Rizwan","year":"2018","journal-title":"BMC Res Notes"},{"issue":"15","key":"2025071419564133200_bnaf010-B248","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1056\/NEJMicm1710426","article-title":"Radial fracture due to parathyroid carcinoma","volume":"379","author":"Suzuki","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"2025071419564133200_bnaf010-B249","first-page":"133","article-title":"Nonfunctional parathyroid cancer \u2212 a case report","volume":"100","author":"\u0160pl\u00edchalov\u00e1","year":"2021","journal-title":"Rozhl Chir"},{"issue":"6","key":"2025071419564133200_bnaf010-B250","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.beem.2018.11.002","article-title":"Parathyroid carcinoma","volume":"32","author":"Salcuni","year":"2018","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"2025071419564133200_bnaf010-B251","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00774-010-0173-4","article-title":"Mediastinal parathyroid carcinoma presenting with severe skeletal manifestations","volume":"28","author":"Yong","year":"2010","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"2025071419564133200_bnaf010-B252","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ando.2015.03.003","article-title":"Parathyroid carcinoma: challenges in diagnosis and treatment","volume":"76","author":"Betea","year":"2015","journal-title":"Ann Endocrinol (Paris)"},{"issue":"2","key":"2025071419564133200_bnaf010-B253","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1097\/SLA.0000000000004144","article-title":"Clinical presentation, treatment, and outcome of parathyroid carcinoma","volume":"275","author":"Lenschow","year":"2022","journal-title":"Ann Surg"},{"issue":"7","key":"2025071419564133200_bnaf010-B254","doi-asserted-by":"crossref","first-page":"919","DOI":"10.4067\/S0034-98872014000700014","article-title":"Brown tumors of the femur and pelvis secondary to a parathyroid carcinoma: report of one case","volume":"142","author":"Radulescu","year":"2014","journal-title":"Rev Med Chil"},{"key":"2025071419564133200_bnaf010-B255","doi-asserted-by":"crossref","first-page":"106259","DOI":"10.1016\/j.ijscr.2021.106259","article-title":"The pathology femoral peritrochanteric fracture with multiple brown tumor as a first sign of parathyroid cancer\u2014a case report","volume":"85","author":"Nguyen","year":"2021","journal-title":"Int J Surg Case Rep"},{"issue":"4","key":"2025071419564133200_bnaf010-B256","first-page":"e230","article-title":"Brown tumors secondary to parathyroid carcinoma masquerading as skeletal metastases on 18F-FDG PET\/CT: a case report","volume":"5","author":"Tsushima","year":"2019","journal-title":"AACE Clin Case Rep"},{"issue":"7","key":"2025071419564133200_bnaf010-B257","doi-asserted-by":"crossref","first-page":"e243478","DOI":"10.1136\/bcr-2021-243478","article-title":"Brown tumour mimicking skeletal metastasis","volume":"14","author":"Parikh","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2025071419564133200_bnaf010-B258","doi-asserted-by":"publisher","first-page":"bcr2016215961","DOI":"10.1136\/bcr-2016-215961","article-title":"Multiple brown tumours from parathyroid carcinoma","volume":"2016","author":"Dagang","year":"2016","journal-title":"BMJ Case Rep"},{"key":"2025071419564133200_bnaf010-B259","doi-asserted-by":"crossref","first-page":"602221","DOI":"10.3389\/fendo.2021.602221","article-title":"Clinical characteristics of primary hyperparathyroidism: 15-year experience of 457 patients in a single center in China","volume":"12","author":"Lin","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2025071419564133200_bnaf010-B260","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cen.13055","article-title":"Preoperative diagnosis and prognosis in 40 parathyroid carcinoma patients","volume":"85","author":"Xue","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"2025071419564133200_bnaf010-B261","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1210\/jc.2007-0585","article-title":"Cinacalcet hydrochloride reduces the Serum calcium concentration in inoperable parathyroid carcinoma","volume":"92","author":"Silverberg","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025071419564133200_bnaf010-B262","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1590\/S0004-27302008000400019","article-title":"Ethanol injection under ultrasound guidance to palliate unresectable parathyroid carcinoma","volume":"52","author":"Montenegro","year":"2008","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"9150","key":"2025071419564133200_bnaf010-B263","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0140-6736(98)06469-1","article-title":"Control of hypercalcaemia of parathyroid carcinoma by immunisation","volume":"353","author":"Bradwell","year":"1999","journal-title":"Lancet"},{"issue":"7","key":"2025071419564133200_bnaf010-B264","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1210\/jc.2003-031911","article-title":"Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma","volume":"89","author":"Betea","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025071419564133200_bnaf010-B265","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s12020-019-02136-z","article-title":"Long-term remission of disseminated parathyroid cancer following immunotherapy","volume":"67","author":"Sarquis","year":"2020","journal-title":"Endocrine"},{"key":"2025071419564133200_bnaf010-B266","doi-asserted-by":"crossref","first-page":"643328","DOI":"10.3389\/fendo.2021.643328","article-title":"Case report: abdominal lymph node metastases of parathyroid carcinoma: diagnostic workup, molecular diagnosis, and clinical management","volume":"12","author":"Lenschow","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2025071419564133200_bnaf010-B267","doi-asserted-by":"crossref","first-page":"e235293","DOI":"10.1136\/bcr-2020-235293","article-title":"Microsatellite instability driven metastatic parathyroid carcinoma managed with the anti-PD1 immunotherapy, pembrolizumab","volume":"13","author":"Park","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"7","key":"2025071419564133200_bnaf010-B268","doi-asserted-by":"crossref","first-page":"luae127","DOI":"10.1210\/jcemcr\/luae127","article-title":"Refractory hypercalcemia secondary to metastatic parathyroid carcinoma treated with immunotherapy","volume":"2","author":"Ta","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"4","key":"2025071419564133200_bnaf010-B269","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.otc.2004.02.004","article-title":"Primary, secondary, and tertiary hyperparathyroidism","volume":"37","author":"Ahmad","year":"2004","journal-title":"Otolaryngol Clin North Am"},{"issue":"12","key":"2025071419564133200_bnaf010-B270","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.3390\/ijms21124332","article-title":"Parathyroid cell proliferation in secondary hyperparathyroidism of chronic kidney disease","volume":"21","author":"Naveh-Many","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"suppl 3","key":"2025071419564133200_bnaf010-B271","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/ndtplus\/sfn079","article-title":"Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention","volume":"1","author":"Goto","year":"2008","journal-title":"Clin Kidney J"},{"issue":"5","key":"2025071419564133200_bnaf010-B272","doi-asserted-by":"crossref","first-page":"E566","DOI":"10.1111\/j.1399-0012.2011.01515.x","article-title":"Intact parathyroid hormone levels in renal transplant patients with normal transplant function","volume":"25","author":"Bleskestad","year":"2011","journal-title":"Clin Transplant"},{"issue":"4","key":"2025071419564133200_bnaf010-B273","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00223-021-00837-0","article-title":"Bone mineral disease after kidney transplantation","volume":"108","author":"Torregrosa","year":"2021","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"2025071419564133200_bnaf010-B274","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jocd.2012.11.012","article-title":"Secondary and tertiary hyperparathyroidism","volume":"16","author":"Jamal","year":"2013","journal-title":"J Clin Densitom"},{"key":"2025071419564133200_bnaf010-B275","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000491041","article-title":"Secondary and tertiary hyperparathyroidism","volume":"51","author":"Messa","year":"2019","journal-title":"Front Horm Res"},{"key":"2025071419564133200_bnaf010-B276","doi-asserted-by":"crossref","first-page":"9619253","DOI":"10.1155\/2018\/9619253","article-title":"Parathyroid hormone fragments: new targets for the diagnosis and treatment of chronic kidney disease-mineral and bone disorder","volume":"2018","author":"Chen","year":"2018","journal-title":"Biomed Res Int"},{"issue":"10","key":"2025071419564133200_bnaf010-B277","first-page":"e72510","article-title":"Intact parathyroid hormone (iPTH) assay: an early approach for bone health assessment in chronic renal failure","volume":"16","author":"Kumari","year":"2024","journal-title":"Cureus"},{"key":"2025071419564133200_bnaf010-B278","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000346791","article-title":"Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis","volume":"180","author":"Koizumi","year":"2013","journal-title":"Contrib Nephrol"},{"issue":"5","key":"2025071419564133200_bnaf010-B279","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.nefroe.2021.11.014","article-title":"Hyporesponsiveness or resistance to the action of parathyroid hormone in chronic kidney disease","volume":"41","author":"Bover","year":"2021","journal-title":"Nefrologia (Engl Ed)"},{"key":"2025071419564133200_bnaf010-B280","doi-asserted-by":"crossref","first-page":"1177829","DOI":"10.3389\/fphys.2023.1177829","article-title":"Pathophysiology of bone disease in chronic kidney disease: from basics to renal osteodystrophy and osteoporosis","volume":"14","author":"Aguilar","year":"2023","journal-title":"Front Physiol"},{"issue":"7","key":"2025071419564133200_bnaf010-B281","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.3390\/biomedicines11072076","article-title":"The potential influence of uremic toxins on the homeostasis of bones and muscles in chronic kidney disease","volume":"11","author":"Hung","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"2025071419564133200_bnaf010-B282","doi-asserted-by":"crossref","first-page":"291","DOI":"10.18231\/j.ijcbr.2020.063","article-title":"Secondary hyperparathyroidism in patients with chronic kidney disease: a case control study","volume":"7","author":"Natikar","year":"2020","journal-title":"Int J Clin Biochem Res"},{"key":"2025071419564133200_bnaf010-B283","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/IJNRD.S282106","article-title":"Correlation between parathyroid hormone levels with urinary magnesium excretion in patients with non-dialysis dependent chronic kidney disease","volume":"13","author":"Carneiro Dias","year":"2020","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"1","key":"2025071419564133200_bnaf010-B284","doi-asserted-by":"crossref","first-page":"15838","DOI":"10.1038\/s41598-023-43016-x","article-title":"Misdiagnosis of chronic kidney disease and parathyroid hormone testing during the past 16 years","volume":"13","author":"Liu","year":"2023","journal-title":"Sci Rep"},{"issue":"24","key":"2025071419564133200_bnaf010-B285","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.2169\/internalmedicine.8618-16","article-title":"Management of osteoporosis in chronic kidney disease","volume":"56","author":"Nitta","year":"2017","journal-title":"Int Med"},{"issue":"2","key":"2025071419564133200_bnaf010-B286","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.semnephrol.2009.01.002","article-title":"Chronic kidney disease\/bone and mineral metabolism: the imperfect storm","volume":"29","author":"Williams","year":"2009","journal-title":"Semin Nephrol"},{"issue":"3","key":"2025071419564133200_bnaf010-B287","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/1744-9987.12678","article-title":"Parathyroid hormone and bone in dialysis patients","volume":"22","author":"Kazama","year":"2018","journal-title":"Ther Apher Dial"},{"issue":"4","key":"2025071419564133200_bnaf010-B288","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.090831","article-title":"Early impairment of trabecular microarchitecture assessed with HR-pQCT in patients with stage II-IV chronic kidney disease","volume":"25","author":"Bacchetta","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025071419564133200_bnaf010-B289","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"issue":"2","key":"2025071419564133200_bnaf010-B290","first-page":"125","article-title":"[Results of bone scintigraphy, densitometry and radiography in secondary hyperparathyroidism in patients with chronic renal failure]","volume":"109","author":"Kosowicz","year":"2003","journal-title":"Pol Arch Med Wewn"},{"issue":"1","key":"2025071419564133200_bnaf010-B291","first-page":"77","article-title":"[The relationship between bone mineral density and secondary hyperparathyroidism bone disease]","volume":"25","author":"Ning","year":"2000","journal-title":"Hunan Yi Ke Da Xue Xue Bao"},{"issue":"1","key":"2025071419564133200_bnaf010-B292","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ki.2013.279","article-title":"High rates of death and hospitalization follow bone fracture among hemodialysis patients","volume":"85","author":"Tentori","year":"2014","journal-title":"Kidney Int"},{"issue":"6","key":"2025071419564133200_bnaf010-B293","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.2008.264","article-title":"Chronic kidney disease and bone fracture: a growing concern","volume":"74","author":"Nickolas","year":"2008","journal-title":"Kidney Int"},{"issue":"2","key":"2025071419564133200_bnaf010-B294","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/archinte.167.2.133","article-title":"Renal function and risk of hip and vertebral fractures in older women","volume":"167","author":"Ensrud","year":"2007","journal-title":"Arch Intern Med"},{"issue":"1","key":"2025071419564133200_bnaf010-B295","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney Int"},{"issue":"1","key":"2025071419564133200_bnaf010-B296","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00198-019-05190-5","article-title":"The association between chronic kidney disease, falls, and fractures: a systematic review and meta-analysis","volume":"31","author":"Goto","year":"2020","journal-title":"Osteoporos Int"},{"issue":"11","key":"2025071419564133200_bnaf010-B297","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1681\/ASN.2005111194","article-title":"Relationship between moderate to severe kidney disease and hip fracture in the United States","volume":"17","author":"Nickolas","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2025071419564133200_bnaf010-B298","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S8756-3282(96)00246-3","article-title":"Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fractures","volume":"19","author":"Yamaguchi","year":"1996","journal-title":"Bone"},{"issue":"4","key":"2025071419564133200_bnaf010-B299","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1053\/ajkd.2002.32006","article-title":"Bone density and heel ultrasound testing do not identify patients with dialysis-dependent renal failure who have had fractures","volume":"39","author":"Jamal","year":"2002","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2025071419564133200_bnaf010-B300","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1053\/j.ajkd.2007.02.264","article-title":"Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis","volume":"49","author":"Jamal","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"2025071419564133200_bnaf010-B301","first-page":"1295","article-title":"[Is it possible to-predict fracture in CKD patients?]","volume":"26","author":"Tsukamoto","year":"2016","journal-title":"Clin Calcium"},{"issue":"5","key":"2025071419564133200_bnaf010-B302","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jbmr.2406","article-title":"Retracted: bone mineral density predicts fractures in chronic kidney disease","volume":"30","author":"West","year":"2015","journal-title":"J Bone Miner Res"},{"key":"2025071419564133200_bnaf010-B303","doi-asserted-by":"crossref","first-page":"100298","DOI":"10.1016\/j.bonr.2020.100298","article-title":"Evaluation of bone densitometry by dual-energy x-ray absorptiometry as a fracture prediction tool in women with chronic kidney disease","volume":"13","author":"G\u00f3mez-Islas","year":"2020","journal-title":"Bone Rep"},{"issue":"2","key":"2025071419564133200_bnaf010-B304","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00198-014-2813-3","article-title":"Low bone mineral density and fractures in stages 3\u20135 CKD: an updated systematic review and meta-analysis","volume":"26","author":"Bucur","year":"2015","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025071419564133200_bnaf010-B305","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfr317","article-title":"Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients\u2014a single-center cohort study","volume":"27","author":"Iimori","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"2025071419564133200_bnaf010-B306","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00198-020-05458-1","article-title":"Trabecular bone score in patients with chronic kidney disease","volume":"31","author":"Rampersad","year":"2020","journal-title":"Osteoporos Int"},{"issue":"1","key":"2025071419564133200_bnaf010-B307","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12882-020-01944-0","article-title":"Trabecular bone score may indicate chronic kidney disease-mineral and bone disorder (CKD-MBD) phenotypes in hemodialysis patients: a prospective observational study","volume":"21","author":"Yun","year":"2020","journal-title":"BMC Nephrol"},{"issue":"S1","key":"2025071419564133200_bnaf010-B308","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10157-016-1369-2","article-title":"Management of secondary hyperparathyroidism: how and why?","volume":"21","author":"Komaba","year":"2017","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"2025071419564133200_bnaf010-B309","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/sdi.12010","article-title":"Vitamin D in dialysis: defining deficiency and rationale for supplementation","volume":"26","author":"Singer","year":"2013","journal-title":"Semin Dial"},{"issue":"6","key":"2025071419564133200_bnaf010-B310","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1681\/ASN.2015040468","article-title":"Ergocalciferol supplementation in hemodialysis patients with vitamin D deficiency: a randomized clinical trial","volume":"27","author":"Miskulin","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2025071419564133200_bnaf010-B311","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000157177","article-title":"Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease","volume":"31","author":"Ok\u0161a","year":"2008","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"2025071419564133200_bnaf010-B312","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2023.04.003","article-title":"Vitamin D therapy in adults with CKD: a systematic review and meta-analysis","volume":"82","author":"Yeung","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2025071419564133200_bnaf010-B313","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3390\/nu15071576","article-title":"Vitamin D and chronic kidney disease association with mineral and bone disorder: an appraisal of tangled guidelines","volume":"15","author":"Bover","year":"2023","journal-title":"Nutrients"},{"issue":"4","key":"2025071419564133200_bnaf010-B314","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/145749690409300407","article-title":"Medical and surgical treatment for secondary and tertiary hyperparathyroidism","volume":"93","author":"Schlosser","year":"2004","journal-title":"Scand J Surg"},{"issue":"4","key":"2025071419564133200_bnaf010-B315","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1525-139X.2005.18406.x","article-title":"VITAMIN D IN HEALTH AND DISEASE: beyond minerals and parathyroid hormone: role of active vitamin D in End-stage renal disease","volume":"18","author":"Wolf","year":"2005","journal-title":"Semin Dial"},{"issue":"3","key":"2025071419564133200_bnaf010-B316","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1744-9987.2007.00422.x","article-title":"Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism","volume":"11","author":"Ogata","year":"2007","journal-title":"Ther Apher Dial"},{"issue":"1","key":"2025071419564133200_bnaf010-B317","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","article-title":"Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism","volume":"79","author":"Wesseling-Perry","year":"2011","journal-title":"Kidney Int"},{"issue":"10","key":"2025071419564133200_bnaf010-B318","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/nep.12505","article-title":"Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2015","journal-title":"Nephrology"},{"issue":"11","key":"2025071419564133200_bnaf010-B319","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1093\/ckj\/sfab091","article-title":"Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis","volume":"14","author":"Cozzolino","year":"2021","journal-title":"Clin Kidney J"},{"issue":"4","key":"2025071419564133200_bnaf010-B320","doi-asserted-by":"crossref","first-page":"e61387","DOI":"10.1371\/journal.pone.0061387","article-title":"Impact of vitamin D on chronic kidney diseases in non-dialysis patients: a meta-analysis of randomized controlled trials","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One"},{"issue":"40","key":"2025071419564133200_bnaf010-B321","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.2174\/1381612829666221027110656","article-title":"A systematic review and meta-analysis of efficacy and safety of calcimimetic agents in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease","volume":"28","author":"Liu","year":"2022","journal-title":"Curr Pharm Des"},{"issue":"s1","key":"2025071419564133200_bnaf010-B322","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1111\/j.1744-9987.2008.00630.x","article-title":"Impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism","volume":"12","author":"Yajima","year":"2008","journal-title":"Ther Apher Dial"},{"issue":"1","key":"2025071419564133200_bnaf010-B323","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00774-009-0102-6","article-title":"Bone metabolism after cinacalcet administration in patients with secondary hyperparathyroidism","volume":"28","author":"Yano","year":"2010","journal-title":"J Bone Miner Metab"},{"issue":"3","key":"2025071419564133200_bnaf010-B324","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1681\/ASN.2004060512","article-title":"Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study","volume":"16","author":"Lindberg","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2025071419564133200_bnaf010-B325","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ki.2014.349","article-title":"Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism","volume":"87","author":"Behets","year":"2015","journal-title":"Kidney Int"},{"issue":"26","key":"2025071419564133200_bnaf010-B326","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"2025071419564133200_bnaf010-B327","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1681\/ASN.2014040414","article-title":"Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial","volume":"26","author":"Moe","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2025071419564133200_bnaf010-B328","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-012-0665-8","article-title":"Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism","volume":"17","author":"Tsuruta","year":"2013","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"2025071419564133200_bnaf010-B329","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.ajkd.2005.04.013","article-title":"Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis","volume":"46","author":"Charytan","year":"2005","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2025071419564133200_bnaf010-B330","first-page":"e36248","article-title":"Effects of cinacalcet on post-transplantation hypercalcemia and hyperparathyroidism in adult kidney transplant patients: a single-center experience","volume":"15","author":"Alpay","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"2025071419564133200_bnaf010-B331","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/ckj\/sfaa005","article-title":"Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics","volume":"14","author":"Arenas","year":"2021","journal-title":"Clin Kidney J"},{"issue":"18","key":"2025071419564133200_bnaf010-B332","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s40265-016-0671-3","article-title":"Etelcalcetide: first global approval","volume":"76","author":"Blair","year":"2016","journal-title":"Drugs"},{"issue":"1","key":"2025071419564133200_bnaf010-B333","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/ki.2013.289","article-title":"AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients","volume":"85","author":"Martin","year":"2014","journal-title":"Kidney Int"},{"issue":"7","key":"2025071419564133200_bnaf010-B334","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.ekir.2019.04.010","article-title":"Etelcalcetide is effective at all levels of severity of secondary hyperparathyroidism in hemodialysis patients","volume":"4","author":"Cunningham","year":"2019","journal-title":"Kidney Int Rep"},{"issue":"12","key":"2025071419564133200_bnaf010-B335","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/j.clinthera.2018.10.016","article-title":"Effects of the intravenous calcimimetic etelcalcetide on bone turnover and Serum fibroblast growth factor 23: post hoc analysis of an open-label study","volume":"40","author":"Shigematsu","year":"2018","journal-title":"Clin Ther"},{"issue":"3","key":"2025071419564133200_bnaf010-B336","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.ajkd.2021.05.020","article-title":"Etelcalcetide utilization, dosing titration, and chronic kidney disease\u2013mineral and bone disease (CKD-MBD) marker responses in US hemodialysis patients","volume":"79","author":"Karaboyas","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2025071419564133200_bnaf010-B337","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5414\/CN110110","article-title":"Etelcalcetide versus placebo for secondary hyperparathyroidism in patients receiving hemodialysis: a meta-analysis of randomized controlled trials","volume":"94","author":"Zhu","year":"2020","journal-title":"Clin Nephrol"},{"issue":"5","key":"2025071419564133200_bnaf010-B338","first-page":"2020-vol5","article-title":"[Long-term efficacy and safety of etelcalcetide in hemodialysis patients with severe secondary hyperparathyroidism]","volume":"37","author":"Massimetti","year":"2020","journal-title":"G Ital Nefrol"},{"issue":"5","key":"2025071419564133200_bnaf010-B339","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/sdi.12734","article-title":"Treatment of secondary hyperparathyroidism: how do cinacalcet and etelcalcetide differ?","volume":"31","author":"Eidman","year":"2018","journal-title":"Semin Dial"},{"issue":"2","key":"2025071419564133200_bnaf010-B340","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of etelcalcetide vs cinacalcet on Serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"2025071419564133200_bnaf010-B341","doi-asserted-by":"crossref","first-page":"e0213774","DOI":"10.1371\/journal.pone.0213774","article-title":"An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism","volume":"14","author":"Block","year":"2019","journal-title":"PLoS One"},{"key":"2025071419564133200_bnaf010-B342","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.bone.2017.08.026","article-title":"Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism","volume":"105","author":"Li","year":"2017","journal-title":"Bone"},{"issue":"2","key":"2025071419564133200_bnaf010-B343","first-page":"197","article-title":"Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet","volume":"43","author":"Pereira","year":"2022","journal-title":"Nefrolog\u00eda (Engl Ed)"},{"issue":"11","key":"2025071419564133200_bnaf010-B344","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2215\/CJN.0000000000000254","article-title":"Changes in bone quality after treatment with etelcalcetide","volume":"18","author":"Khairallah","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2025071419564133200_bnaf010-B345","doi-asserted-by":"crossref","first-page":"e0195316","DOI":"10.1371\/journal.pone.0195316","article-title":"A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro","volume":"13","author":"Kawata","year":"2018","journal-title":"PLoS One"},{"issue":"10","key":"2025071419564133200_bnaf010-B346","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s40261-018-0687-4","article-title":"Pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy Japanese subjects: first-in-human phase I study","volume":"38","author":"Akizawa","year":"2018","journal-title":"Clin Drug Investig"},{"issue":"10","key":"2025071419564133200_bnaf010-B347","doi-asserted-by":"crossref","first-page":"e0204896","DOI":"10.1371\/journal.pone.0204896","article-title":"Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: a randomized, double-blind, placebo-controlled, dose-finding study","volume":"13","author":"Akizawa","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"2025071419564133200_bnaf010-B348","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10157-019-01692-y","article-title":"Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients","volume":"23","author":"Tsuruya","year":"2019","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"2025071419564133200_bnaf010-B349","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1038\/s41598-019-42017-z","article-title":"Long-term efficacy and safety of evocalcet in Japanese patients with secondary hyperparathyroidism receiving hemodialysis","volume":"9","author":"Yokoyama","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"2025071419564133200_bnaf010-B350","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2215\/CJN.02550508","article-title":"Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue","volume":"4","author":"Toussaint","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2025071419564133200_bnaf010-B351","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"issue":"10","key":"2025071419564133200_bnaf010-B352","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMc062792","article-title":"Prolonged bisphosphonate release after treatment in children","volume":"356","author":"Papapoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"2","key":"2025071419564133200_bnaf010-B353","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MNH.0000000000000585","article-title":"Bisphosphonate therapy in CKD","volume":"29","author":"Damasiewicz","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"2025071419564133200_bnaf010-B354","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1742-7843.2005.pto_160.x","article-title":"Acute renal effects of intravenous bisphosphonates in the rat","volume":"97","author":"Pfister","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"2025071419564133200_bnaf010-B355","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","article-title":"Toxic acute tubular necrosis following treatment with zoledronate (zometa)","volume":"64","author":"Markowitz","year":"2003","journal-title":"Kidney Int"},{"issue":"5","key":"2025071419564133200_bnaf010-B356","doi-asserted-by":"crossref","first-page":"e18.1","DOI":"10.1016\/S0272-6386(03)00214-2","article-title":"Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity","volume":"41","author":"Banerjee","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2025071419564133200_bnaf010-B357","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2141.2002.03826.x","article-title":"Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma","volume":"119","author":"Desikan","year":"2002","journal-title":"Br J Haematol"},{"issue":"6","key":"2025071419564133200_bnaf010-B358","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","article-title":"Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate","volume":"12","author":"MARKOWITZ","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2025071419564133200_bnaf010-B359","first-page":"288","article-title":"[Use of bisphosphonates in chronic kidney disease]","volume":"30","author":"Torregrosa","year":"2010","journal-title":"Nefrologia (Engl Ed)"},{"issue":"3","key":"2025071419564133200_bnaf010-B360","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000276666","article-title":"Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series","volume":"29","author":"Amerling","year":"2010","journal-title":"Blood Purif"},{"key":"2025071419564133200_bnaf010-B361","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.bone.2019.07.007","article-title":"Skeletal levels of bisphosphonate in the setting of chronic kidney disease are independent of remodeling rate and lower with fractionated dosing","volume":"127","author":"Swallow","year":"2019","journal-title":"Bone"},{"issue":"12","key":"2025071419564133200_bnaf010-B362","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","article-title":"Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the cockcroft and gault method: a pooled analysis of nine clinical trials","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025071419564133200_bnaf010-B363","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2025071419564133200_bnaf010-B364","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/M16-2752","article-title":"Benefits and Harms of osteoporosis medications in patients with chronic kidney disease","volume":"166","author":"Wilson","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"2025071419564133200_bnaf010-B365","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12882-017-0478-9","article-title":"Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials","volume":"18","author":"Shigematsu","year":"2017","journal-title":"BMC Nephrol"},{"issue":"4","key":"2025071419564133200_bnaf010-B366","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00774-018-0977-1","article-title":"Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan","volume":"37","author":"Sugimoto","year":"2019","journal-title":"J Bone Miner Metab"},{"key":"2025071419564133200_bnaf010-B367","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1046\/j.1523-1755.63.s85.21.x","article-title":"Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis","volume":"63","author":"Torregrosa","year":"2003","journal-title":"Kidney Int"},{"key":"2025071419564133200_bnaf010-B368","doi-asserted-by":"crossref","first-page":"20543581241283523","DOI":"10.1177\/20543581241283523","article-title":"The efficacy and safety of bisphosphonate therapy for osteopenia\/osteoporosis in patients with chronic kidney disease: a systematic review and individual patient-level meta-analysis of placebo-controlled randomized trials","volume":"11","author":"Whitlock","year":"2024","journal-title":"Can J Kidney Health Dis"},{"issue":"4","key":"2025071419564133200_bnaf010-B369","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1440-1797.2005.00436.x","article-title":"Effects of short-term alendronate on bone mineral density in haemodialysis patients","volume":"10","author":"Wetmore","year":"2005","journal-title":"Nephrology(Carlton)"},{"issue":"1","key":"2025071419564133200_bnaf010-B370","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s00774-012-0391-z","article-title":"Oral alendronate can suppress bone turnover but not fracture in kidney transplantation recipients with hyperparathyroidism and chronic kidney disease","volume":"31","author":"Yamamoto","year":"2013","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"2025071419564133200_bnaf010-B371","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11255-015-1133-7","article-title":"Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up","volume":"48","author":"Tillmann","year":"2016","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"2025071419564133200_bnaf010-B372","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00198-019-05267-1","article-title":"Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients","volume":"31","author":"McKee","year":"2020","journal-title":"Osteoporos Int"},{"issue":"8","key":"2025071419564133200_bnaf010-B373","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2025071419564133200_bnaf010-B374","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgaa851","article-title":"Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease","volume":"106","author":"Broadwell","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025071419564133200_bnaf010-B375","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2025071419564133200_bnaf010-B376","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s11255-024-04110-9","article-title":"Is denosumab an efficient and safe drug for osteoporosis in dialysis patients? Considerations and state of the art about its use in this setting","volume":"56","author":"Simonini","year":"2024","journal-title":"Int Urol Nephrol"},{"issue":"7","key":"2025071419564133200_bnaf010-B377","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/jbmr.2480","article-title":"Sustained modeling-based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab","volume":"30","author":"Ominsky","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2025071419564133200_bnaf010-B378","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2215\/CJN.0000000000000213","article-title":"Long-term effect of denosumab on bone disease in patients with CKD","volume":"18","author":"Iseri","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"2025071419564133200_bnaf010-B379","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1210\/jc.2014-1154","article-title":"An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis","volume":"99","author":"Chen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025071419564133200_bnaf010-B380","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1111\/imj.12283","article-title":"Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure","volume":"43","author":"Farinola","year":"2013","journal-title":"Intern Med J"},{"issue":"3","key":"2025071419564133200_bnaf010-B381","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1620\/tjem.238.205","article-title":"Combination therapy of denosumab and calcitriol for a renal transplant recipient with severe bone loss due to therapy-resistant hyperparathyroidism","volume":"238","author":"Wada","year":"2016","journal-title":"Tohoku J Exp Med"},{"issue":"7","key":"2025071419564133200_bnaf010-B382","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1681\/ASN.2007050555","article-title":"The effect of raloxifene treatment in postmenopausal women with CKD","volume":"19","author":"Ishani","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2025071419564133200_bnaf010-B383","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ki.2010.378","article-title":"Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis","volume":"79","author":"Melamed","year":"2011","journal-title":"Kidney Int"},{"issue":"6","key":"2025071419564133200_bnaf010-B384","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1046\/j.1523-1755.2003.00005.x","article-title":"Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis","volume":"63","author":"Hern\u00e1ndez","year":"2003","journal-title":"Kidney Int"},{"issue":"11","key":"2025071419564133200_bnaf010-B385","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1055\/a-1655-4362","article-title":"Raloxifene in the treatment of osteoporosis in postmenopausal women with End-stage renal disease: a systematic review and meta-analysis","volume":"53","author":"Ma","year":"2021","journal-title":"Horm Metab Res"},{"issue":"6","key":"2025071419564133200_bnaf010-B386","first-page":"461","article-title":"Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5","volume":"8","author":"Haghverdi","year":"2014","journal-title":"Iran J Kidney Dis"},{"issue":"19","key":"2025071419564133200_bnaf010-B387","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"2025071419564133200_bnaf010-B388","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int"},{"key":"2025071419564133200_bnaf010-B389","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2147\/CIA.S120175","article-title":"Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study","volume":"11","author":"Nishikawa","year":"2016","journal-title":"Clin Interv Aging"},{"issue":"12","key":"2025071419564133200_bnaf010-B390","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s00198-024-07260-9","article-title":"Association between renal function and fracture incidence during treatment with teriparatide or alendronate: an exploratory subgroup analysis of the Japanese osteoporosis intervention trial-05","volume":"35","author":"Takeuchi","year":"2024","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025071419564133200_bnaf010-B391","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.afos.2023.11.002","article-title":"Teriparatide and etelcalcetide improve bone, fibrosis, and fat parameters in chronic kidney disease model rats","volume":"9","author":"Igarashi","year":"2023","journal-title":"Osteoporos Sarcopenia"},{"issue":"4","key":"2025071419564133200_bnaf010-B392","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00198-016-3861-7","article-title":"Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia","volume":"28","author":"Ota","year":"2017","journal-title":"Osteoporos Int"},{"issue":"2","key":"2025071419564133200_bnaf010-B393","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/1744-9987.12867","article-title":"Impact of weekly teriparatide on the bone and mineral metabolism in hemodialysis patients with relatively low Serum parathyroid hormone: a pilot study","volume":"24","author":"Yamamoto","year":"2020","journal-title":"Ther Apher Dial"},{"issue":"6","key":"2025071419564133200_bnaf010-B394","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/j.ajkd.2015.01.025","article-title":"Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report","volume":"65","author":"Palcu","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2025071419564133200_bnaf010-B395","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","article-title":"Sclerostin deficiency in humans","volume":"96","author":"van Lierop","year":"2017","journal-title":"Bone"},{"issue":"23","key":"2025071419564133200_bnaf010-B396","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1093\/ajhp\/zxaa285","article-title":"Romosozumab: a first-in-class sclerostin inhibitor for osteoporosis","volume":"77","author":"Prather","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2025071419564133200_bnaf010-B397","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bone.2016.12.012","article-title":"Clinical utility of anti-sclerostin antibodies","volume":"96","author":"McClung","year":"2017","journal-title":"Bone"},{"issue":"8","key":"2025071419564133200_bnaf010-B398","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/jbmr.4563","article-title":"Efficacy and safety of romosozumab among postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease","volume":"37","author":"Miller","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025071419564133200_bnaf010-B399","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s00774-021-01253-y","article-title":"Efficacy of romosozumab in patients with osteoporosis on maintenance hemodialysis in Japan; an observational study","volume":"39","author":"Sato","year":"2021","journal-title":"J Bone Miner Metab"},{"issue":"12","key":"2025071419564133200_bnaf010-B400","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00198-022-06534-4","article-title":"Romosozumab successfully regulated progressive osteoporosis in a patient with autosomal dominant polycystic kidney disease undergoing hemodialysis","volume":"33","author":"Suzuki","year":"2022","journal-title":"Osteoporos Int"},{"key":"2025071419564133200_bnaf010-B401","doi-asserted-by":"crossref","first-page":"101639","DOI":"10.1016\/j.bonr.2022.101639","article-title":"Romosozumab improves low bone mineral density in a postmenopausal woman undergoing chronic hemodialysis and treated with a calcium-sensing receptor agonist","volume":"17","author":"Ogata","year":"2022","journal-title":"Bone Rep"},{"issue":"1","key":"2025071419564133200_bnaf010-B402","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00223-022-01031-6","article-title":"One-year Romosozumab treatment followed by one-year denosumab treatment for osteoporosis in patients on hemodialysis: an observational study","volume":"112","author":"Saito","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2025071419564133200_bnaf010-B403","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/sdi.12772","article-title":"Parathyroidectomy in dialysis patients: indications, methods, and consequences","volume":"32","author":"Rodr\u00edguez-Ortiz","year":"2019","journal-title":"Semin Dial"},{"issue":"5","key":"2025071419564133200_bnaf010-B404","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2265.2011.04265.x","article-title":"Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism","volume":"76","author":"Lu","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025071419564133200_bnaf010-B405","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0272-6386(03)00909-0","article-title":"Changes of bone remodeling immediately after parathyroidectomy for secondary hyperparathyroidism","volume":"42","author":"Yajima","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"1-2","key":"2025071419564133200_bnaf010-B406","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000486172","article-title":"Influence of parathyroidectomy on bone metabolism and bone pain in patients with secondary hyperparathyroidism","volume":"59","author":"Schneider","year":"2018","journal-title":"Eur Surg Res"},{"issue":"8","key":"2025071419564133200_bnaf010-B407","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s11255-019-02217-y","article-title":"Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism","volume":"51","author":"Ge","year":"2019","journal-title":"Int Urol Nephrol"},{"issue":"7","key":"2025071419564133200_bnaf010-B408","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/00365513.2017.1354256","article-title":"Effects of parathyroidectomy on bone metabolism in haemodialysis patients with secondary hyperparathyroidism","volume":"77","author":"Ma","year":"2017","journal-title":"Scand J Clin Lab Invest"},{"issue":"7","key":"2025071419564133200_bnaf010-B409","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/s41430-020-00829-7","article-title":"Effect of parathyroidectomy on bone tissue biomarkers and body composition in patients with chronic kidney disease and secondary hyperparathyroidism","volume":"75","author":"Siqueira","year":"2021","journal-title":"Eur J Clin Nutr"},{"issue":"4","key":"2025071419564133200_bnaf010-B410","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.ajkd.2023.10.007","article-title":"Impact of parathyroidectomy versus oral cinacalcet on bone mineral density in patients on peritoneal dialysis with advanced secondary hyperparathyroidism: the PROCEED pilot randomized trial","volume":"83","author":"Wang","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2025071419564133200_bnaf010-B411","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/nu15010167","article-title":"Bone disease in chronic kidney disease and kidney transplant","volume":"15","author":"Bellorin-Font","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"2025071419564133200_bnaf010-B412","doi-asserted-by":"crossref","first-page":"2210231","DOI":"10.1080\/0886022X.2023.2210231","article-title":"Mineral and bone disorder after kidney transplantation: a single-center cohort study","volume":"45","author":"Sun","year":"2023","journal-title":"Ren Fail"},{"issue":"2","key":"2025071419564133200_bnaf010-B413","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000110875","article-title":"Abnormal bone and mineral metabolism in kidney transplant patients\u2014a review","volume":"28","author":"Sprague","year":"2008","journal-title":"Am J Nephrol"},{"issue":"5","key":"2025071419564133200_bnaf010-B414","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1097\/TP.0000000000004099","article-title":"Improvement of mineral and bone disorders after renal transplantation","volume":"106","author":"Ferreira","year":"2022","journal-title":"Transplantation"},{"issue":"9","key":"2025071419564133200_bnaf010-B415","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/nep.14301","article-title":"The comprehensive incidence and risk factors of fracture in kidney transplant recipients: a meta-analysis","volume":"29","author":"Jia","year":"2024","journal-title":"Nephrology"},{"issue":"11-12","key":"2025071419564133200_bnaf010-B416","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1159\/000533125","article-title":"Risk factors for fractures in renal transplantation: a population-based cohort study","volume":"54","author":"Tsai","year":"2023","journal-title":"Am J Nephrol"},{"issue":"6","key":"2025071419564133200_bnaf010-B417","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3390\/jcm12062337","article-title":"Time-varying risk factors for incident fractures in kidney transplant recipients: a nationwide cohort study in South Korea","volume":"12","author":"Eum","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"2025071419564133200_bnaf010-B418","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1681\/ASN.2013080851","article-title":"Kidney transplantation with early corticosteroid withdrawal: paradoxical effects at the central and peripheral Skeleton","volume":"25","author":"Iyer","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"2025071419564133200_bnaf010-B419","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/TP.0b013e3181814b00","article-title":"Parathyroidectomy followed by kidney transplantation can improve bone mineral density in patients with secondary hyperparathyroidism","volume":"86","author":"Chou","year":"2008","journal-title":"Transplantation"},{"issue":"6","key":"2025071419564133200_bnaf010-B420","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1210\/jc.2015-3908","article-title":"Epidemiology and diagnosis of hypoparathyroidism","volume":"101","author":"Clarke","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025071419564133200_bnaf010-B421","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1210\/clinem\/dgaa113","article-title":"Hypoparathyroidism","volume":"105","author":"Bilezikian","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025071419564133200_bnaf010-B422","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1590\/0004-2730000003399","article-title":"Bone disease in hypoparathyroidism","volume":"58","author":"Clarke","year":"2014","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"3","key":"2025071419564133200_bnaf010-B423","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12020-020-02324-2","article-title":"Diagnosis and management of hypocalcemia","volume":"69","author":"Pepe","year":"2020","journal-title":"Endocrine"},{"key":"2025071419564133200_bnaf010-B424","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000491043","article-title":"Classification of hypoparathyroid disorders","volume":"51","author":"Cianferotti","year":"2019","journal-title":"Front Horm Res"},{"issue":"18","key":"2025071419564133200_bnaf010-B425","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMcp1800213","article-title":"Hypoparathyroidism","volume":"380","author":"Gafni","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"2025071419564133200_bnaf010-B426","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/jbmr.4005","article-title":"Changes in skeletal microstructure through four continuous years of rhPTH(1\u201384) therapy in hypoparathyroidism","volume":"35","author":"Cusano","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025071419564133200_bnaf010-B427","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s12020-019-01858-4","article-title":"Huge variations in definition and reported incidence of postsurgical hypoparathyroidism: a systematic review","volume":"64","author":"Harsl\u00f8f","year":"2019","journal-title":"Endocrine"},{"issue":"2","key":"2025071419564133200_bnaf010-B428","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1001\/archsurg.2007.55","article-title":"Hypoparathyroidism after total thyroidectomy","volume":"143","author":"Asari","year":"2008","journal-title":"Archives of Surgery"},{"issue":"5","key":"2025071419564133200_bnaf010-B429","doi-asserted-by":"crossref","first-page":"zrac102","DOI":"10.1093\/bjsopen\/zrac102","article-title":"Definition and diagnosis of postsurgical hypoparathyroidism after thyroid surgery: meta-analysis","volume":"6","author":"Nagel","year":"2022","journal-title":"BJS Open"},{"issue":"12","key":"2025071419564133200_bnaf010-B430","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/jbmr.4691","article-title":"Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"key":"2025071419564133200_bnaf010-B431","first-page":"3962951","article-title":"A case of \u201clate\u201d postsurgical hypoparathyroidism","volume":"2017","author":"Sim\u00f5es","year":"2017","journal-title":"Case Rep Endocrinol"},{"issue":"6","key":"2025071419564133200_bnaf010-B432","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF03350718","article-title":"Late-onset hypocalcemia appearing years after thyroid surgery","volume":"12","author":"Halperin","year":"1989","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2025071419564133200_bnaf010-B433","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.21873\/invivo.12128","article-title":"Identification of patients at high risk for postsurgical hypoparathyroidism","volume":"34","author":"Kakava","year":"2020","journal-title":"In Vivo (Brooklyn)"},{"issue":"2","key":"2025071419564133200_bnaf010-B434","doi-asserted-by":"crossref","first-page":"101","DOI":"10.17691\/stm2020.12.2.13","article-title":"Postoperative hypoparathyroidism: prognosis, prevention, and treatment (review)","volume":"12","author":"Melikyan","year":"2020","journal-title":"Sovrem Tekhnologii Med"},{"issue":"2","key":"2025071419564133200_bnaf010-B435","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/8756-3282(95)00443-2","article-title":"Bone histomorphometry in hypoparathyroid patients treated with vitamin D","volume":"18","author":"Langdahl","year":"1996","journal-title":"Bone"},{"issue":"12","key":"2025071419564133200_bnaf010-B436","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1359\/jbmr.080803","article-title":"Dynamic and structural properties of the Skeleton in hypoparathyroidism","volume":"23","author":"Rubin","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025071419564133200_bnaf010-B437","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bone.2009.09.020","article-title":"Three dimensional cancellous bone structure in hypoparathyroidism","volume":"46","author":"Rubin","year":"2010","journal-title":"Bone"},{"issue":"6","key":"2025071419564133200_bnaf010-B438","first-page":"1617","article-title":"Bone mineral density in patients with chronic hypoparathyroidism","volume":"76","author":"Abugassa","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025071419564133200_bnaf010-B439","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jbmr.2609","article-title":"Noninvasive assessment of skeletal microstructure and estimated bone strength in hypoparathyroidism","volume":"31","author":"Cusano","year":"2016","journal-title":"J Bone Miner Res"},{"issue":"2","key":"2025071419564133200_bnaf010-B440","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00198-016-3750-0","article-title":"Bone imaging in hypoparathyroidism","volume":"28","author":"Silva","year":"2017","journal-title":"Osteoporos Int"},{"issue":"7","key":"2025071419564133200_bnaf010-B441","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1210\/jc.2002-021388","article-title":"Increased bone mineral density in patients with chronic hypoparathyroidism","volume":"88","author":"Chan","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025071419564133200_bnaf010-B442","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1210\/jc.2003-030470","article-title":"Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects","volume":"88","author":"Chen","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025071419564133200_bnaf010-B443","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-019-05177-2","article-title":"PTH and bone material strength in hypoparathyroidism as measured by impact microindentation","volume":"31","author":"Starr","year":"2020","journal-title":"Osteoporos Int"},{"issue":"9","key":"2025071419564133200_bnaf010-B444","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jbmr.2501","article-title":"The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study","volume":"30","author":"Underbjerg","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025071419564133200_bnaf010-B445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6823-13-1","article-title":"Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density","volume":"13","author":"Mendon\u00e7a","year":"2013","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"2025071419564133200_bnaf010-B446","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/clinem\/dgab076","article-title":"Vertebral fracture assessment in postmenopausal women with postsurgical hypoparathyroidism","volume":"106","author":"Cipriani","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025071419564133200_bnaf010-B447","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s40618-022-01818-2","article-title":"Vertebral fractures, trabecular bone score and their determinants in chronic hypoparathyroidism","volume":"45","author":"Saha","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"2025071419564133200_bnaf010-B448","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/jbmr.2273","article-title":"Postsurgical hypoparathyroidism-risk of fractures, psychiatric diseases, cancer, cataract, and infections","volume":"29","author":"Underbjerg","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2025071419564133200_bnaf010-B449","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/jbmr.4871","article-title":"Risk of fractures in thyroid cancer patients with postoperative hypoparathyroidism: a nationwide cohort study in Korea","volume":"38","author":"Ahn","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025071419564133200_bnaf010-B450","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/jbmr.3328","article-title":"Bone Status among patients with nonsurgical hypoparathyroidism, autosomal dominant hypocalcaemia, and pseudohypoparathyroidism: a cohort study","volume":"33","author":"Underbjerg","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025071419564133200_bnaf010-B451","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1210\/jc.2016-3292","article-title":"Vertebral fractures and bone mineral density in patients with idiopathic hypoparathyroidism on long term follow-up","volume":"102","author":"Chawla","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025071419564133200_bnaf010-B452","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1007\/s00198-021-05966-8","article-title":"Fracture risk in hypoparathyroidism: a systematic review and meta-analysis","volume":"32","author":"Pal","year":"2021","journal-title":"Osteoporos Int"},{"issue":"6","key":"2025071419564133200_bnaf010-B453","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025071419564133200_bnaf010-B454","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1530\/eje.0.1460215","article-title":"Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D","volume":"146","author":"Arlt","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025071419564133200_bnaf010-B455","doi-asserted-by":"crossref","first-page":"e10586","DOI":"10.1002\/jbm4.10586","article-title":"The influence of conventional treatment on symptoms and complaints in patients with chronic postsurgical hypoparathyroidism","volume":"6","author":"Stamm","year":"2022","journal-title":"JBMR Plus"},{"issue":"6","key":"2025071419564133200_bnaf010-B456","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1210\/jc.2015-3910","article-title":"Management of hypoparathyroidism: present and future","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025071419564133200_bnaf010-B457","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00198-009-1149-x","article-title":"Therapy of hypoparathyroidism with intact parathyroid hormone","volume":"21","author":"Rubin","year":"2010","journal-title":"Osteoporos Int"},{"issue":"10","key":"2025071419564133200_bnaf010-B458","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025071419564133200_bnaf010-B459","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1\u201384): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025071419564133200_bnaf010-B460","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/jbmr.452","article-title":"PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism","volume":"26","author":"Rubin","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025071419564133200_bnaf010-B461","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/jbmr.1493","article-title":"Changes in 3-dimensional bone structure indices in hypoparathyroid patients treated with PTH(1-84): a randomized controlled study","volume":"27","author":"Sikjaer","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2025071419564133200_bnaf010-B462","doi-asserted-by":"crossref","first-page":"e10829","DOI":"10.1002\/jbm4.10829","article-title":"Transitory activation and improved transition from erosion to formation within intracortical bone remodeling in hypoparathyroid patients treated with rhPTH (1\u201384)","volume":"7","author":"van Dijk Christiansen","year":"2023","journal-title":"JBMR Plus"},{"issue":"7","key":"2025071419564133200_bnaf010-B463","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1089\/thy.2017.0309","article-title":"American thyroid association statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults","volume":"28","author":"Orloff","year":"2018","journal-title":"Thyroid"},{"issue":"4","key":"2025071419564133200_bnaf010-B464","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2025071419564133200_bnaf010-B465","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4158\/EP15936.OR","article-title":"An open-label extension study of parathyroid hormone rhpth(1-84) in adults with hypoparathyroidism","volume":"22","author":"Lakatos","year":"2016","journal-title":"Endocr Pract"},{"issue":"11","key":"2025071419564133200_bnaf010-B466","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/jc.2019-01010","article-title":"Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism","volume":"104","author":"Mannstadt","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025071419564133200_bnaf010-B467","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/jbmr.3543","article-title":"The effects of long-term administration of rhPTH(1-84) in hypoparathyroidism by bone histomorphometry","volume":"33","author":"Rubin","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025071419564133200_bnaf010-B468","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/jbmr.4780","article-title":"The clinical and skeletal effects of long-term therapy of hypoparathyroidism with rhPTH (1\u201384)","volume":"38","author":"Agarwal","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025071419564133200_bnaf010-B469","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/jbmr.4566","article-title":"Safety and efficacy of PTH 1\u201334 and 1\u201384 therapy in chronic hypoparathyroidism: a meta-analysis of prospective trials","volume":"37","author":"Puliani","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025071419564133200_bnaf010-B470","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1\u201334 vs calcitriol and calcium in the treatment of hypoparathyroidism","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA"},{"issue":"10","key":"2025071419564133200_bnaf010-B471","first-page":"3480","article-title":"A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1\u201334 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025071419564133200_bnaf010-B472","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once Versus twice-daily parathyroid hormone 1\u201334 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025071419564133200_bnaf010-B473","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1\u201334) Versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025071419564133200_bnaf010-B474","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1210\/jc.2009-2464","article-title":"Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium","volume":"95","author":"Winer","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025071419564133200_bnaf010-B475","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1210\/jc.2015-1855","article-title":"PTH(1\u201334) for surgical hypoparathyroidism: a prospective, open-label investigation of efficacy and quality of life","volume":"100","author":"Santonati","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025071419564133200_bnaf010-B476","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/jc.2017-01555","article-title":"PTH(1\u201334) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life","volume":"103","author":"Palermo","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2025071419564133200_bnaf010-B477","doi-asserted-by":"crossref","first-page":"115977","DOI":"10.1016\/j.bone.2021.115977","article-title":"Therapy with PTH 1\u201334 or calcitriol and calcium in diverse etiologies of hypoparathyroidism over 27 years at a single tertiary care center","volume":"149","author":"Winer","year":"2021","journal-title":"Bone"},{"issue":"3","key":"2025071419564133200_bnaf010-B478","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr"},{"key":"2025071419564133200_bnaf010-B479","first-page":"5593653","article-title":"Desperate times call for desperate measures: use of continuous subcutaneous 1-34 PTH infusion for postsurgical hypoparathyroidism","volume":"2021","author":"Haider","year":"2021","journal-title":"Case Rep Endocrinol"},{"issue":"8","key":"2025071419564133200_bnaf010-B480","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1627","article-title":"Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure","volume":"27","author":"Gafni","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2025071419564133200_bnaf010-B481","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1002\/jbmr.4676","article-title":"Parathyroid hormone therapy for managing chronic hypoparathyroidism: a systematic review and meta-analysis","volume":"37","author":"Yao","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2025071419564133200_bnaf010-B482","doi-asserted-by":"crossref","first-page":"bvae053","DOI":"10.1210\/jendso\/bvae053","article-title":"Continuous subcutaneous delivery of rhPTH(1-84) and rhPTH(1-34) by pump in adults with hypoparathyroidism","volume":"8","author":"Charoenngam","year":"2024","journal-title":"J Endocr Soc"},{"issue":"11","key":"2025071419564133200_bnaf010-B483","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jbmr.3824","article-title":"Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism","volume":"34","author":"Holten-Andersen","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025071419564133200_bnaf010-B484","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/jbmr.4016","article-title":"A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults","volume":"35","author":"Karpf","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025071419564133200_bnaf010-B485","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025071419564133200_bnaf010-B486","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2025071419564133200_bnaf010-B487","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41574-018-0042-0","article-title":"Diagnosis and management of pseudohypoparathyroidism and related disorders: first international consensus statement","volume":"14","author":"Mantovani","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2025071419564133200_bnaf010-B488","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1210\/jc.2011-1048","article-title":"Pseudohypoparathyroidism: diagnosis and treatment","volume":"96","author":"Mantovani","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025071419564133200_bnaf010-B489","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1002\/jbmr.3450","article-title":"Genetic and epigenetic defects at the GNAS locus lead to distinct patterns of skeletal growth but similar early-onset obesity","volume":"33","author":"Hanna","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2025071419564133200_bnaf010-B490","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/1055665618814661","article-title":"Cranio-maxillofacial and dental findings in Albright's hereditary osteodystrophy and pseudohypoparathyroidism","volume":"56","author":"Schlund","year":"2019","journal-title":"Cleft Palate Craniofac J"},{"issue":"3","key":"2025071419564133200_bnaf010-B491","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000508985","article-title":"Recommendations for diagnosis and treatment of pseudohypoparathyroidism and related disorders: an updated practical tool for physicians and patients","volume":"93","author":"Mantovani","year":"2020","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"2025071419564133200_bnaf010-B492","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s11914-023-00787-6","article-title":"Variable bone phenotypes in patients with pseudohypoparathyroidism","volume":"21","author":"Wang","year":"2023","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"2025071419564133200_bnaf010-B493","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/cen.14496","article-title":"Bone turnover markers are associated with the PTH levels in different subtypes of pseudohypoparathyroidism type 1 patients","volume":"95","author":"Duan","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2025071419564133200_bnaf010-B494","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/jbmr.3360","article-title":"Bone mineral density and its serial changes are associated with PTH levels in pseudohypoparathyroidism type 1B patients","volume":"33","author":"Chu","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2025071419564133200_bnaf010-B495","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/eje.0.1440263","article-title":"Skeletal responsiveness to parathyroid hormone in pseudohypoparathyroidism","volume":"144","author":"Kanatani","year":"2001","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025071419564133200_bnaf010-B496","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-10-0795","article-title":"Osteosclerosis in two brothers with autosomal dominant pseudohypoparathyroidism type 1b: bone histomorphometric analysis","volume":"164","author":"Sbrocchi","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2025071419564133200_bnaf010-B497","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/cge.13734","article-title":"A paternally inherited non-sense variant c.424G &gt; T (p.G142*) in the first exon of XL\u03b1s in an adult patient with hypophosphatemia and osteopetrosis","volume":"97","author":"Chen","year":"2020","journal-title":"Clin Genet"},{"issue":"9","key":"2025071419564133200_bnaf010-B498","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1210\/jc.2010-0498","article-title":"Bone mineral density in pseudohypoparathyroidism type 1a","volume":"95","author":"Long","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025071419564133200_bnaf010-B499","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/cen.12948","article-title":"Pseudohypoparathyroidism\u2014epidemiology, mortality and risk of complications","volume":"84","author":"Underbjerg","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7","key":"2025071419564133200_bnaf010-B500","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1359\/jbmr.2000.15.7.1412","article-title":"Serial changes in bone mineral density and bone turnover after correction of secondary hyperparathyroidism in a patient with pseudohypoparathyroidism type ib","volume":"15","author":"Tollin","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2025071419564133200_bnaf010-B501","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1210\/jc.2012-1655","article-title":"Development and treatment of tertiary hyperparathyroidism in patients with pseudohypoparathyroidism type 1B","volume":"97","author":"Neary","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025071419564133200_bnaf010-B502","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00467-015-3271-7","article-title":"Cinacalcet as adjunctive therapy in pseudohypoparathyroidism type 1b","volume":"31","author":"Srivastava","year":"2016","journal-title":"Pediatric Nephrology"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnaf010\/62848323\/bnaf010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/46\/4\/576\/62848323\/bnaf010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/46\/4\/576\/62848323\/bnaf010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T23:57:41Z","timestamp":1752537461000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/46\/4\/576\/8104766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":502,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,3]]},"published-print":{"date-parts":[[2025,7,15]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnaf010","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,3]]}}}